<SEC-DOCUMENT>0001193125-26-245181.txt : 20260528
<SEC-HEADER>0001193125-26-245181.hdr.sgml : 20260528
<ACCEPTANCE-DATETIME>20260528160517
ACCESSION NUMBER:		0001193125-26-245181
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260521
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260528
DATE AS OF CHANGE:		20260528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STANDARD BIOTOOLS INC.
		CENTRAL INDEX KEY:			0001162194
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				770513190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34180
		FILM NUMBER:		261035549

	BUSINESS ADDRESS:	
		STREET 1:		50 MILK STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		6502666000

	MAIL ADDRESS:	
		STREET 1:		50 MILK STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLUIDIGM CORP
		DATE OF NAME CHANGE:	20011113
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lab-20260521.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-05-28T15:37:47.6893+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:lab="http://www.standardbio.com/20260521" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_598da5f5-87b0-4237-9990-99cb2f9aa57a" name="dei:AmendmentFlag" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" format="ixt:fixed-false"> false</ix:nonNumeric><ix:nonNumeric id="F_3e6564b9-1b2f-414d-82d2-9a66f1ede7f1" name="dei:EntityCentralIndexKey" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041">0001162194</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lab-20260521.xsd"/></ix:references><ix:resources><xbrli:context id="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001162194</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-21</xbrli:startDate><xbrli:endDate>2026-05-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:14pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9c093fe-deb7-4060-87b4-180b145c9447" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Securities Exchange Act of 1934</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Report (date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f7dc7a2-1770-477d-a218-c8f8b16d8d61" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 21, 2026</span></ix:nonNumeric></span></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0ea5844-17c2-4f24-8f11-98c9f5191673" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard BioTools Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33%;box-sizing:content-box;"/>
     <td style="width:34%;box-sizing:content-box;"/>
     <td style="width:33%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f0781409-1d90-4467-bc90-c9fd3b8e5b8a" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_cf3c254c-baef-488b-b243-fcb3003ed9f9" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-34180</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3cc45e3e-e08d-4b9a-8a6d-52c470d34086" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">77-0513190</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(I.R.S. Employer Identification Number)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_52601732-0d5e-49da-b700-e119fab26516" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">50 Milk Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_7ae3452d-d8b7-46a1-a638-27ecea327d11" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10th Floor</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_16a67af3-7376-4bfb-bb5e-f18a6f9695a8" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_342434ff-a242-4767-a83b-c946ef35f7fa" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_3bec15bd-f7af-4de9-b7b3-cd36020f1510" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02109</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Address of principal executive offices and zip code)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span><ix:nonNumeric id="F_a31c211e-dc13-48c6-84e0-e5675743740f" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">) </span><span><ix:nonNumeric id="F_548f9525-304e-47c3-962d-a28f41987f18" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">266-6000</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Registrant's telephone number, including area code)</span></p></td>
    </tr>
   </table><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:5.96%;box-sizing:content-box;"/>
     <td style="width:94.04%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2c1392a0-0ca5-4eaa-884b-298a442eb3f1" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.352%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b44c5859-0c5a-454a-9f83-af96c0eb08e5" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d8f814e4-b7d3-4dc1-a961-59ecb5a3ed87" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2b2b678d-08c5-40ed-b75e-5dfb2ae372f5" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:40%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:40%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="5" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a7b3f892-ad6b-466f-8145-2327f1e41e4a" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4c809a99-ba97-4c14-af53-ba6e40ae0205" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LAB</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c26e2d3e-fabd-4806-bd04-fef080d84c2b" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company    </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b50b7a5-d362-4374-8d37-57aecff265ba" contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2026 Change of Control and Severance Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 21, 2026, the Board of Directors (the &#8220;Board&#8221;) of Standard BioTools Inc. (the &#8220;Company&#8221;) approved the Company&#8217;s 2026 Change of Control and Severance Plan and Participation Agreement thereunder (the &#8220;2026 Severance Plan&#8221;). The 2026 Severance Plan has a term until August 4, 2028. The 2026 Severance Plan is intended to provide certain payments of cash severance and other benefits to the Company&#8217;s executive leadership team in the event of a qualifying termination of employment with the Company, other than for the Company&#8217;s Chief Executive Officer who is party to a Participation Agreement under the Company&#8217;s 2023 Change of Control and Severance Plan (as amended and restated, the &#8220;2023 Severance Plan&#8221;) as further described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain members of the Company&#8217;s executive leadership team, and certain other designated employees are eligible to participate in the 2026 Severance Plan and to receive benefits thereunder. On May 27, 2026, each of Alex Kim (the Company&#8217;s Chief Financial Officer) and Sean Mackay (the Company&#8217;s Chief Business Officer) entered into Participation Agreements under the 2026 Severance Plan (together, the &#8220;Non-CEO Participation Agreements&#8221;), copies of which are filed herewith as Exhibits 10.2 and 10.3, respectively. For such individuals, the 2026 Severance Plan supersedes the severance and/or change in control related benefits previously provided to such individuals under t</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he Company&#8217;s 2024 Change of Control and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Plan and any prior </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employment and severance agreements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2026 Severance Plan, if the executive&#8217;s employment is terminated outside of the period beginning three months before a Change of Control (as defined in the 2026 Severance Plan) and ending 12 months after a Change of Control (such period, the &#8220;Change of Control Period&#8221;) for a reason other than Cause (as defined in the 2026 Severance Plan) or the executive&#8217;s death or Disability (as defined in the 2026 Severance Plan), then, subject to the severance conditions provided in the 2026 Severance Plan, the executive will be entitled to receive the following severance benefits:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  Continued payments (less applicable withholdings) totaling 100% of the executive&#8217;s annual base salary in effect as of the date of termination in equal installments over a period of 12 months.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  A pro-rated lump-sum payment of the executive&#8217;s annual target bonus in effect immediately prior to the termination.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  Reimbursement of costs of continued health coverage for the executive, his or her spouse, and/or his or her dependents, as applicable, for a period of up to 12 months.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  If the termination occurs on or prior to August 27, 2026, 100% vesting acceleration of the executive&#8217;s then-outstanding and unvested equity awards, provided that, if an equity award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless expressly otherwise provided in the applicable equity award agreement, 100% of such equity award will vest assuming the applicable performance criteria had been achieved at target levels for the relevant performance period(s).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  Reasonable outplacement services in accordance with any applicable policy of the Company that is in effect as of the executive&#8217;s termination (or if no such policy is in effect, as determined by the Company).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2026 Severance Plan, if an executive&#8217;s employment is terminated within the Change of Control Period either (i) by the Company for a reason other than Cause or the executive&#8217;s death or Disability or (ii) by the executive for Good Reason (as defined in the executive&#8217;s Participation Agreement under the 2026 Severance Plan), then, subject to the severance conditions provided in the 2026 Severance Plan, the executive will be entitled to receive the following severance benefits:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  A lump-sum payment (less applicable withholdings) totaling 150% of the sum of (x) his or her annual base salary (as in effect immediately before termination or immediately before the Change of Control, whichever is higher) plus (y) the greater of (A) his or her annual target bonus (as in effect immediately before termination or immediately before the Change of Control, whichever is higher) or (B) the average of the annual cash incentives actually paid to him or her for the three fiscal years preceding the year in which his or her termination occurs; provided, however, that if the annual bonus with respect to the most recently preceding fiscal year has not yet been paid, his or her annual target bonus will be used as the bonus for that year in calculating the average.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  A pro-rated lump-sum payment of the executive&#8217;s annual target bonus in effect immediately prior to the Change of Control or the termination, whichever is greater.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  Reimbursement of costs for continued health coverage for the executive, his or her spouse, and/or his or her dependents, as applicable, for a period of up to 18 months.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  100% vesting acceleration of his or her then-outstanding and unvested equity awards, provided that, if an equity award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless otherwise provided in the applicable equity award agreement, 100% of such equity award will vest assuming the applicable performance criteria had been achieved at target levels for the relevant performance period(s).</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing descriptions of the 2026 Severance Plan and the form of Participation Agreement thereunder and the Non-CEO Participation Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of the 2026 Severance Plan, including the form of Participation Agreement thereunder, and the Non-CEO Participation Agreements, copies  of which are filed as Exhibits 10.1, 10.2 and 10.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Change of Control and Severance Plan, As Amended and Restated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, on May 21, 2026, the Board approved the 2023 Severance Plan. The 2023 Severance Plan has an initial term until August 4, 2028, subject to automatic one-year renewals thereunder unless non-renewed by the Company upon twelve months&#8217; prior notice. The 2023 Severance Plan is intended to provide certain payments of cash severance and other benefits to certain members of the Company&#8217;s executive leadership team in the event of a qualifying termination of employment with the Company. On May 22, 2026, the Company&#8217;s Chief Executive Officer, Michael Egholm, Ph.D., entered into a  participation agreement under the 2023 Severance Plan (the &#8220;Egholm Participation Agreement&#8221;), a copy of which is filed herewith as Exhibit 10.5. Dr. Egholm is the only participant under the 2023 Severance Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2023 Severance Plan, if an executive&#8217;s employment is terminated outside of the Change of Control Period for a reason other than Cause (as defined in the 2023 Severance Plan) or the executive&#8217;s death or Disability (as defined in the 2023 Severance Plan), the executive will be entitled to receive the following severance benefits:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  Continued payments (less applicable withholdings) totaling 200% of the executive&#8217;s annual base salary in effect as of the date of termination in equal installments over a period of 24 months.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  Reimbursement of costs of continued health coverage for the executive, his or her spouse, and/or his or her dependents, as applicable, for a period of up to 12 months.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  Reasonable outplacement services in accordance with any applicable policy of the Company that is in effect as of the executive&#8217;s termination (or if no such policy is in effect, as determined by the Company).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2023 Severance Plan, if an executive&#8217;s employment is terminated within the Change of Control Period either (i) by the Company for a reason other than Cause or the executive&#8217;s death or Disability or (ii) by the executive for Good Reason (as defined in the executive&#8217;s Participation Agreement under the 2023 Severance Plan), the executive will be entitled to receive the following severance benefits:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  A lump-sum payment (less applicable withholdings) totaling 250% of the sum of (x) his or her annual base salary (as in effect immediately before termination or immediately before the Change of Control, whichever is higher) plus (y) the greater of (A) his or her annual target bonus (as in effect immediately before termination or immediately before the Change of Control, whichever is higher) or (B) the average of the annual bonuses actually paid to him or her for the three fiscal years preceding the year in which termination occurs; provided, however, that if the annual bonus with respect to the most recently preceding fiscal year has not yet been paid, his or her annual target bonus will be used as the bonus for that year in calculating the average.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  A pro-rated lump-sum payment of the executive&#8217;s annual target bonus in effect immediately prior to the Change of Control or the termination, whichever is greater.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149; Reimbursement of costs for continued health coverage for the executive, his or her spouse, and/or his or her dependents, as applicable, for a period of up to 30 months.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  100% vesting acceleration of his or her then-outstanding and unvested equity awards, provided that, if an equity award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless otherwise provided in the applicable equity award agreement, 100% of such equity award will vest assuming the applicable performance criteria had been achieved at target levels for the relevant performance period(s).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing descriptions of the 2023 Severance Plan and the form of Participation Agreement thereunder and the Egholm Participation Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the 2023 Severance Plan, including the form of Participation Agreement thereunder, and the Egholm Participation Agreement,  copies of which are filed as Exhibits 10.4 and 10.5, respectively to this Current Report on Form 8-K and are incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 - Financial Statements and Exhibits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:1.5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.28%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lab-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2026 Change of Control and Severance Plan and Participation Agreement</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.343%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.352%;text-align:left;"><a href="lab-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2026 Change of Control and Severance Plan Participation Agreement, dated as of May 27, 2026, by and between Standard BioTools Inc. and Alex Kim.</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.343%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.352%;text-align:left;"><a href="lab-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2026 Change of Control and Severance Plan Participation Agreement, dated as of May 27, 2026, by and between Standard BioTools Inc. and Sean MacKay.</span></a></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.343%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.352%;text-align:left;"><a href="lab-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2023 Change of Control and Severance Plan Participation Agreement, as amended and restated.</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.343%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.352%;text-align:left;"><a href="lab-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2023 Change of Control and Severance Plan and Participation Agreement, dated as of May 22, 2026, by and between Standard BioTools Inc. and Michael Egholm, Ph.D.</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.343%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:0.9pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.173%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.352%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+  Management compensation plan or arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:36%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.324%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 28, 2026</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">STANDARD BIOTOOLS INC.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.324%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alex Kim</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.324%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alex Kim</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.324%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.324%;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.324%;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>lab-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-28T15:37:47.7572+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STANDARD BIOTOOLS INC.</font></p><p style="font-size:10pt;margin-top:13.8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026 CHANGE OF CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION</font></p><p style="font-size:10pt;margin-top:13.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adopted May 21, 2026</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.1pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;justify-content:flex-start;min-width:2.4%;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Introduction</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The purpose of this Standard BioTools Inc. 2026 Change of Control and Severance Plan, or Plan (as defined in Section 2 below), is to provide assurances of specified benefits to certain employees of the Company whose employment is subject to being involuntarily terminated other than for death, Disability, or Cause or voluntarily terminated for Good Reason under the circumstances described herein. This Plan is an &#x201c;employee welfare benefit plan,&#x201d; as defined in Section 3(1) of the U.S. Employee Retirement Income Security Act of 1974, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan. This Plan is a replacement for that certain Standard BioTools Inc. Change of Control and Severance Plan and Summary Plan Description adopted by the Compensation Committee of Standard BioTools Inc. on August 27, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Prior Plan expires according to its terms and will not be renewed. By becoming a Participant under this Plan (and immediately upon execution of the Participation Agreement), the Participant expressly acknowledges that Participant will cease being a participant under or entitled to any benefits under the Prior Plan</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.25pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;justify-content:flex-start;min-width:2.4%;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Important Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The following words and phrases, when the initial letter of the term is capitalized, will have the meanings set forth in this Section 2, unless a different meaning is plainly required by the context:</font></div></div><p style="text-indent:12.667%;font-size:10pt;margin-top:11.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Human Capital Committee whose members have been delegated duty by the Board to act as the Administrator of the Plan within the meaning of Section 3(16)(A) of ERISA, or another duly constituted committee that has been delegated such duty by the Board, or any person to whom the Board has delegated any authority or responsibility with respect to the Plan pursuant to Section 12, but only to the extent of such delegation.</font></p><p style="margin-left:12.667%;font-size:10pt;margin-top:6.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:4.15pt;font-family:Times New Roman;margin-bottom:26.15pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; exists upon (i) a Participant&#x2019;s conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (ii) a Participant&#x2019;s (a) engagement in material dishonesty, willful misconduct, or gross negligence&#x2014;in each case in connection with the Participant&#x2019;s position at the Company; (b) breach of any confidentiality, invention assignment, non-disclosure, or non-solicitation agreement entered into between the Company and the Participant; (c) material violation of a written Company policy or procedure that has been provided to the Participant, which violation causes substantial injury to the Company; or (d) willful refusal to perform the Participant&#x2019;s assigned duties to the Company, following written notice of such refusal by the Company and a period of fifteen (15) days to cure the same and the Participant&#x2019;s failure to cure during such time period. No act or omission shall be considered &#x201c;willful&#x201d; if such act or omission was done, or not done, in the reasonable, good-faith belief that such act or omission was in the best interests of the Company or upon the advice of counsel to the Company.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:26.15pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Change of Control&#x201d; means the occurrence of any of the following events:</font></p><p style="margin-left:1.333%;text-indent:17.568%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4.1. Change in Ownership of the Company. A change in the ownership of the Company which occurs on the date that any &#x201c;Person&#x201d; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company pursuant to a transaction or a series of related transactions; provided, however, that for purposes of this subsection 2.4.1, the acquisition of additional stock by any one Person, who is considered to own more than 50% of the total voting power of the stock of the Company will not be considered a Change of Control; or</font></p><p style="margin-left:1.333%;text-indent:17.568%;font-size:10pt;margin-top:11.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4.2. Change in Effective Control of the Company. A change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:1.333%;font-size:10pt;margin-top:11.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subsection 2.4.2, if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change of Control; or</font></p><p style="margin-left:1.333%;text-indent:17.568%;font-size:10pt;margin-top:10.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4.3. Merger or Sale of the Company&#x2019;s Assets. A merger or consolidation of the Company or any of its subsidiaries whether or not approved by the Board of Directors, or the sale or disposition by the Company of all or substantially all of the Company&#x2019;s assets in a transaction requiring shareholder approval; provided, however, that for purposes of this subsection 2.4.3, the following will not constitute a Change of Control: (A) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such entity) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B) a transfer of assets by the Company to: (1) an entity that is controlled by the Company&#x2019;s stockholders immediately after the transfer, (2) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#x2019;s stock, (3) an entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (4) a Person, that owns, directly or indirectly, 50% or more of the total value or voting power of all the outstanding stock of the Company, or (5) an entity, at least 50% of the total value or voting power of which is owned, directly or indirectly, by a Person described in subsection 2.4.3(B)(4).</font></p><p style="margin-left:1.333%;font-size:10pt;margin-top:14.35pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, a transaction will not be deemed a Change of Control unless the transaction qualifies as a change in control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.</font></p><p style="margin-left:1.333%;font-size:10pt;margin-top:11.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, a transaction will not constitute a Change of Control if: (i) its sole purpose is to change the state of the Company&#x2019;s incorporation, (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transaction or (iii) its sole purpose is to obtain funding for the Company in a financing that is approved by the Board.</font></p><p style="margin-left:1.333%;font-size:10pt;margin-top:11.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notwithstanding any of the foregoing, however</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in any circumstance or transaction in which compensation or benefits paid under this Plan would result in imposition of an additional tax under Section 409A of the Code if the foregoing definition of &#x201c;Change of Control&#x201d; were to apply, but would not result in the imposition of any additional tax if the term &#x201c;Change of Control&#x201d; were defined herein to mean a &#x201c;change in control event&#x201d; within the meaning of Treasury Regulation Section 1.409A-3(i)(5), then &#x201c;Change of Control&#x201d; shall mean a &#x201c;change in control event&#x201d; within the meaning of Treasury Regulation Section 1.409A-3(i)(5), but only to the extent necessary to prevent such compensation from becoming subject to an additional tax under Section 409A.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Change of Control Period&#x201d; means the time period beginning three (3) months prior to a Change of Control and ending on the date that is twelve (12) months following the Change of Control.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Code&#x201d; means the Internal Revenue Code of 1986, as amended. Reference to a specific section of the Code or regulation thereunder shall include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Company&#x201d; means Standard BioTools Inc. and any successor that assumes the obligations of the Company under the Plan by way of merger, acquisition, consolidation or other transaction.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Disability&#x201d; means that Participant has been unable to perform his or her Company duties as the result of Participant&#x2019;s incapacity due to physical or mental illness, and such inability, at least twenty-six (26) weeks after its commencement, is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to Participant or Participant&#x2019;s legal representative (such agreement as to acceptability not to be unreasonably withheld). Termination resulting from Disability may only be effected after at least 30 days&#x2019; written notice by the Company of its intention to terminate Participant&#x2019;s employment. In the event that Participant resumes the performance of substantially all of his or her duties hereunder before the termination of employment becomes effective, the notice of intent to terminate will automatically be deemed to have been revoked.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:14.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Effective Date&#x201d; means May 21, 2026, which is the date the Plan was deemed effective by the Human Capital Committee of the Board.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:12.667%;font-size:10pt;margin-top:11.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.10.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Exchange Act&#x201d; means the U.S. Securities Exchange Act of 1934, as amended.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.11.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Equity Awards&#x201d; means a Participant&#x2019;s outstanding stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance stock units, and any other Company equity compensation awards.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.12.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Good Reason&#x201d; has the meaning set forth in the Participant&#x2019;s Participation Agreement.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.13.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Involuntary Termination&#x201d; means a Non-COC Involuntary Termination or a COC Involuntary Termination, in each case, under the circumstances described in Section 4 or Section 5, as applicable.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.14.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Participant&#x201d; means an employee of the Company or of any parent or subsidiary of the Company who (a) has been designated by the Administrator to participate in the Plan and (b) has timely and properly executed and delivered a Participation Agreement to the Company.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.15.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Participation Agreement&#x201d; means the individual agreement (as will be provided in separate cover as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) provided by the Administrator to a Participant under the Plan, which has been signed and accepted by the Participant.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.16.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Plan&#x201d; means the Standard BioTools Inc. 2026 Change of Control and Severance Plan as set forth in this document and as hereafter amended from time to time.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.17.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Section 409A of the Code and the final regulations and any guidance promulgated thereunder.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.18.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Section 409A Limit&#x201d; means two (2) times the lesser of: (i) the Participant&#x2019;s annualized compensation based upon the annual rate of pay paid to the Participant during the taxable year preceding the taxable year of the Participant&#x2019;s termination of employment as determined under, and with such adjustments as are set forth in, Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which the Participant&#x2019;s employment is terminated.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.19.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Severance Benefits&#x201d; means the compensation and other benefits that the Participant will be provided in the circumstances described in Section 4 or Section 5 of the Plan, as applicable.</font></p><div class="item-list-element-wrapper" style="text-indent:6.757%;font-size:0;margin-top:14.6pt;justify-content:flex-start;margin-bottom:0;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligibility for Severance Benefits. An individual is eligible for Severance Benefits under the Plan, as described in Section 4 or Section 5, as applicable, only if he or she experiences an Involuntary Termination.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.4pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Involuntary Termination Outside the Change of Control Period. If, outside of the Change of Control Period, the Company (or any parent or subsidiary of the Company) terminates the Participant&#x2019;s employment for a reason other than for Cause, the Participant&#x2019;s death or Disability (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-COC Involuntary Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), subject to the Participant&#x2019;s compliance with Section 7, the Participant will receive the following Severance Benefits:</font></div></div><p style="text-indent:12.667%;font-size:10pt;margin-top:11.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits. Continued payments of cash severance and/or a bonus payment for the periods set forth in the Participant&#x2019;s Participation Agreement;</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued Medical Benefits. If the Participant and any spouse and/or other dependents of the Participant (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Family Members</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) have coverage on the date of the Participant&#x2019;s Involuntary Termination under a group health plan sponsored by the Company, the Company will pay on behalf of Participant the total applicable premium cost for continued group health plan coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COBRA</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) during the period of time following the Participant&#x2019;s employment termination, as set forth in the Participant&#x2019;s Participation Agreement, provided that the Participant validly elects and is eligible to continue coverage under COBRA for the Participant and any such Family Members; and</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.3.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services. Reasonable outplacement services in accordance with any applicable Company policy in effect as of the Participant&#x2019;s Non-COC Involuntary Termination (or if no such policy is in effect, as determined by the Company, in its sole discretion).</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.6pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Involuntary Termination During the Change of Control Period. If, during the Change of Control Period, (i) a Participant terminates his or her employment with the Company (or any parent or subsidiary of the Company) for Good Reason, or (ii) the Company (or any parent or subsidiary of the Company) terminates the Participant&#x2019;s employment for a reason other than Cause or the Participant&#x2019;s death or Disability (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COC Involuntary Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then, in each case, subject to the Participant&#x2019;s compliance with Section 7, the Participant will receive the following Severance Benefits:</font></div></div><p style="text-indent:12.667%;font-size:10pt;margin-top:11.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits. A lump-sum payment of cash severance and/or bonus equal to the amount set forth in the Participant&#x2019;s Participation Agreement;</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Award Vesting Acceleration Benefit. The Participant&#x2019;s Equity Awards will accelerate and vest to the amount set forth in the Participant&#x2019;s Participation Agreement, as applicable;</font></p><p style="text-indent:12%;font-size:10pt;margin-top:14.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.3.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued Medical Benefits. If the Participant, and any Family Member(s) has/have coverage on the date of the Participant&#x2019;s Involuntary Termination under a group health plan sponsored by the Company, the Company will pay on behalf of Participant the total applicable premium cost for continued group health plan coverage under the COBRA during the period of time following the Participant&#x2019;s employment termination, as set forth in the Participant&#x2019;s Participation Agreement, provided that the Participant validly elects and is eligible to continue coverage under COBRA for the Participant and his or her Family Members; and</font></p><p style="text-indent:12%;font-size:10pt;margin-top:11.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services. Reasonable outplacement services in accordance with any applicable Company policy in effect as of the Participant&#x2019;s COC Involuntary Termination (or if no such policy is in effect, as determined by the Company, in its sole discretion); provided, however, that such outplacement services shall be in no case less than the outplacement services provided under any applicable Company policy in effect immediately prior to the applicable Change of Control.</font></p><p style="text-indent:6%;font-size:10pt;margin-top:11.15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation on Payments. In the event that the severance and other benefits provided for in this Plan or otherwise (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">280G Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) payable to a Participant (i) constitute &#x201c;parachute payments&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this Section 6, would be subject to the excise tax imposed by Section 4999 of the Code, then the 280G Payments will be either:</font></p><p style="margin-left:12%;font-size:10pt;margin-top:6.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delivered in full, or</font></p><p style="text-indent:12%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delivered as to such lesser extent as would result in no portion of such benefits being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by the Participant on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999. If a reduction in severance and other benefits constituting &#x201c;parachute payments&#x201d; is necessary so that benefits are delivered to a lesser extent, reduction will occur in the following order: (a) cancellation of awards granted &#x201c;contingent on a change in ownership or control&#x201d; (within the meaning of Code Section 280G); (b) a pro rata reduction of (i) cash payments that are subject to Section 409A as deferred compensation and (ii) cash payments not subject to Section 409A; (c) a pro rata reduction of (i) employee benefits that are subject to Section 409A as deferred compensation and (ii) employee benefits not subject to Section 409A; and (d) a pro rata cancellation of (i) accelerated vesting equity awards that are subject to Section 409A as deferred compensation and (ii) equity awards not subject to Section 409A. In the event that acceleration of vesting of equity awards is to be cancelled, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Participant&#x2019;s equity awards. Notwithstanding the foregoing, to the extent the Company submits any payment or benefit payable to the Participant under this Plan or otherwise to the Company&#x2019;s stockholders for approval in accordance with Treasury Regulation Section 1.280G-1 Q&amp;A 7, the foregoing provisions shall not apply following such submission and such payments and benefits will be treated in accordance with the results of such vote, except that any reduction in, or waiver of, such payments or benefits required by such vote will be applied without any application of discretion by the Participant and in the order prescribed by this Section 6.</font></p><p style="font-size:10pt;margin-top:11.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 6 will be made in writing by the Company&#x2019;s independent public accountants immediately prior to the Change of Control or such other person or entity to which the parties mutually agree (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), whose determination will be conclusive and binding upon the Participant and the Company. For purposes of making the calculations required by this Section 6 the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Participant and the Company will furnish to the Firm such information and documents as the Firm may reasonably request in order to make</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:11.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination under this Section 6. The Company will bear all costs the Firm may incur in connection with any calculations contemplated by this Section 6.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6.65pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to Receipt of Severance.</font></div></div><p style="text-indent:12%;font-size:10pt;margin-top:4.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release Agreement. As a condition to receiving the Severance Benefits under this Plan, each Participant will be required to sign and not revoke a separation and release of claims agreement in substantially the form attached this Plan as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix B</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). In all cases, the Release must become effective and irrevocable no later than the 60th day following the Participant&#x2019;s Involuntary Termination (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Release Deadline Date</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). If the Release does not become effective and irrevocable by the Release Deadline Date, the Participant will forfeit any right to the Severance Benefits. In no event will the Severance Benefits be paid or provided until the Release becomes effective and irrevocable.</font></p><p style="text-indent:12%;font-size:10pt;margin-top:11.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Requirements. A Participant&#x2019;s receipt of Severance Benefits will be subject to the Participant continuing to comply with the provisions of this Section 7 and the terms of any confidentiality, proprietary information and inventions agreement and such other appropriate agreement between the Participant and the Company. Severance Benefits under this Plan will terminate immediately for a Participant if the Participant, at any time, violates any such agreement and/or the provisions of this Section 7.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.4pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Timing of Severance Benefits. Provided that the Release becomes effective and irrevocable by the Release Deadline Date and subject to Section 10, the Severance Benefits will be paid (or in the case of Severance Benefits scheduled to be paid installments, will commence) on the first Company payroll date following the Release Deadline Date (such payment date, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Severance Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and any severance payments or benefits otherwise payable to the Participant during the period immediately following the Participant&#x2019;s termination of employment with the Company through the Severance Start Date will be paid in a lump sum to the Participant on the Severance Start Date, with any remaining payments to be made as provided in this Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:14.5pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exclusive Benefit. The benefits provided under this Plan shall be the exclusive benefit for a Participant related to termination of employment and/or change in control and shall supersede and replace any severance and/or change in control benefits set forth in any offer letter, employment agreement and/or severance agreement, including without limitation the Prior Plan. For the avoidance of doubt, if a Participant was otherwise eligible to participate in any other Company severance plan (whether or not subject to ERISA), then participation in this Plan will supersede and replace eligibility in such other plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6.95pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A.</font></div></div><p style="text-indent:12.667%;font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.1. Notwithstanding anything to the contrary in this Plan, no severance payments or benefits to be paid or provided to a Participant, if any, under this Plan that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will be paid or provided until the Participant has a &#x201c;separation from service&#x201d; within the meaning of Section 409A. Similarly, no severance payable to a Participant, if any, under this Plan that otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A 1(b)(9) will be payable until the Participant has a &#x201c;separation from service&#x201d; within the meaning of Section 409A.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is intended that none of the severance payments or benefits under this Plan will constitute Deferred Payments but rather will be exempt from Section 409A as a payment that would fall within the &#x201c;short-term deferral period&#x201d; as described in Section 10.3 below or resulting from an involuntary separation from service as described in Section 10.4 below. In no event will a Participant have discretion to determine the taxable year of payment of any Deferred Payment.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.3. Notwithstanding anything to the contrary in this Plan or in any Participation Agreement, if a Participant is a &#x201c;specified employee&#x201d; within the meaning of Section 409A at the time of the Participant&#x2019;s separation from service (other than due to death), then the Deferred Payments, if any, that are payable within the first six (6) months following the Participant&#x2019;s separation from service, will become payable on the date six (6) months and one (1) day following the date of the Participant&#x2019;s separation from service. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, in the event of the Participant&#x2019;s death following the Participant&#x2019;s separation from service, but before the six- month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of the Participant&#x2019;s death and all other Deferred Payments will be payable in accordance with the</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Plan is intended to constitute a separate payment under Section 1.409A-2(b)(2) of the Treasury Regulations.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:14.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.4.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any amount paid under this Plan that satisfies the requirements of the &#x201c;short-term deferral&#x201d; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of Section 10 above.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.5.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any amount paid under this Plan that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Payments for purposes of Section 10 above.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.6. The foregoing provisions are intended to comply with or be exempt from the requirements of Section 409A so that none of the payments and benefits to be provided under the Plan will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply or be exempt. Notwithstanding anything to the contrary in the Plan, including but not limited to Sections 12 and 15, the Company reserves the right to amend the Plan as it deems necessary or advisable, in its sole discretion and without the consent of the Participants, to comply with Section 409A or to avoid income recognition under Section 409A prior to the actual payment of benefits under the Plan or imposition of any additional tax. In no event will the Company reimburse a Participant for any taxes that may be imposed on the Participant as result of Section 409A.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;justify-content:flex-start;min-width:2.4%;">11.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholdings</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will withhold from any payments or benefits under the Plan all applicable U.S. federal, state, local and non-U.S. taxes required to be withheld and any other required payroll deductions.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.25pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;justify-content:flex-start;min-width:2.4%;">12.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Plan will be administered and interpreted by the Administrator (in its sole discretion). The Administrator is the &#x201c;named fiduciary&#x201d; of the Plan for purposes of ERISA and will be subject to the fiduciary standards of ERISA when acting in such capacity. Any decision made or other action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document, will be conclusive and binding on all persons and be given the maximum possible deference allowed by law. In accordance with Section 2.1, the Administrator (a) may, in its sole discretion and on such terms and conditions as it may provide, further delegate in writing to one or more officers of the Company all or any portion of its authority or responsibility with respect to the Plan, and (b) has the authority to act for the Company (in a non-fiduciary capacity) as to any matter pertaining to the Plan; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that any Plan amendment or termination or any other action that reasonably could be expected to increase materially the cost of the Plan must be approved by the Board.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.05pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;justify-content:flex-start;min-width:2.4%;">13.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligibility to Participate</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent that the Administrator has delegated administrative authority or responsibility to one or more officers of the Company in accordance with Sections 2.1 and 12, each such officer will not be excluded from participating in the Plan if otherwise eligible, but he or she is not entitled to act upon or make determinations regarding any matters pertaining specifically to his or her own benefit or eligibility under the Plan. The Administrator will act upon and make determinations regarding any matters pertaining specifically to the benefit or eligibility of each such officer under the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:14.65pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term. This Plan will have a term until August 4, 2028 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). If a Participant becomes entitled to benefits during the Term, the Plan will not terminate with respect to such Participant until all of the obligations of the Company and such Participant with respect to this Plan have been satisfied.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.85pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment or Termination. The Company, by action of the Administrator, reserves the right to amend or terminate the Plan at any time, without advance notice to any Participant and without regard to the effect of the amendment or termination on any individual; provided, however, that during the Term, the Company may not, without a Participant&#x2019;s written consent, amend or terminate the Plan in any way, nor take any other action, that (i) prevents that Participant from becoming eligible for the Severance Benefits under the Plan, or (ii) reduces or alters to the detriment of the Participant the Severance Benefits payable, or potentially payable, to a Participant under the Plan (including, without limitation, imposing additional conditions). Any amendment or termination of the Plan will be in writing. Any action of the Company in amending or terminating the Plan will be taken in a non-fiduciary capacity.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6.95pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims and Appeals.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:12.667%;font-size:10pt;margin-top:4.8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims Procedure. Any employee or other person who believes he or she is entitled to any payment under the Plan may submit a claim in writing to the Administrator within 90 days of the earlier of (i) the date the claimant learned the amount of his or her benefits under the Plan or (ii) the date the claimant learned that he or she will not be entitled to any benefits under the Plan. If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice also will describe any additional information needed to support the claim and an explanation of why such material or information is necessary, and the Plan&#x2019;s procedures for appealing the denial, including a statement of the claimant&#x2019;s right to bring a civil action under Section 502(a) of ERISA following an adverse benefit determination on review. The denial notice will be provided within 90 days after the claim is received. If special circumstances require an extension of time for processing the claim (up to 90 days from the end of the initial 90-day period), written notice of the extension will be given prior to the end of the initial 90-day period. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision on the claim.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16.2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appeal Procedure. If the claimant&#x2019;s claim is denied, the claimant (or his or her authorized representative) may apply in writing to the Administrator for a review of the decision denying the claim. Review must be requested within 60 days following the date the claimant received the written notice of their claim denial or else the claimant loses the right to review. The claimant shall be provided the opportunity to submit written comments, documents, records, and other information relating to the claim for benefits. The claimant (or representative) has the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit issues and comments in writing. The Administrator will provide written notice of its decision on review within 60 days after it receives a review request. If additional time (up to 60 days from the end of the initial period) is needed to review the request, the claimant (or representative) will be given written notice of the reason for the delay. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision. If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice also will include a statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents and other information relevant to the claim, and a statement regarding the claimant&#x2019;s right to bring an action under Section 502(a) of ERISA within two (2) years after completing the Plan&#x2019;s claims and appeal procedures. Any action shall be resolved exclusively through binding arbitration in accordance with the terms and procedures of the Participant&#x2019;s Mutual Arbitration Agreement.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.35pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attorneys&#x2019; Fees. The parties shall each bear their own expenses, legal fees and other fees incurred in connection with this Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.15pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Source of Payments. All payments under the Plan will be paid from the general funds of the Company; no separate fund will be established under the Plan, and the Plan will have no assets. No right of any person to receive any payment under the Plan will be any greater than the right of any other general unsecured creditor of the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.3pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inalienability. In no event may any current or former employee of the Company or any of its subsidiaries or affiliates sell, transfer, anticipate, assign or otherwise dispose of any right or interest under the Plan. At no time will any such right or interest be subject to the claims of creditors nor liable to attachment, execution or other legal process.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.05pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">20.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Enlargement of Employment Rights. Neither the establishment or maintenance or amendment of the Plan, nor the making of any benefit payment hereunder, will be construed to confer upon any individual any right to continue to be an employee of the Company. The Company expressly reserves the right to discharge any of its employees at any time, with or without cause. However, as described in the Plan, a Participant may be entitled to benefits under the Plan depending upon the circumstances of his or her termination of employment.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.35pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">21.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors. Any successor to the Company of all or substantially all of the Company&#x2019;s business and/or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or other transaction) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under the Plan, the term &#x201c;Company&#x201d; will include any successor to the Company&#x2019;s business and/or assets which become bound by the terms of the Plan by operation of law, or otherwise.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:14.6pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">22.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Law. The provisions of the Plan will be construed, administered and enforced in accordance with ERISA and, to the extent applicable, the internal substantive laws of the state of California (but not its conflict of laws provisions).</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.35pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">23.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability. If any provision of the Plan is held invalid or unenforceable, its invalidity or unenforceability will not affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.1pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">24.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings. Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the meaning hereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.5pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">25.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification. The Company hereby agrees to indemnify and hold harmless the officers and employees of the Company, and the members of its Board, from all losses, claims, costs or other liabilities arising from their acts or omissions in connection with the administration, amendment or termination of the Plan, to the maximum extent permitted by applicable law. This indemnity will cover all such liabilities, including judgments, settlements and costs of defense. The Company will provide this indemnity from its own funds to the extent that insurance does not cover such liabilities. This indemnity is in addition to and not in lieu of any other indemnity provided to such person by the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:13.85pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">26.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Information.</font></div></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:63.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34.921%;box-sizing:content-box;"></td>
     <td style="width:65.079%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Name:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. 2026 Change of Control and Severance Plan</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Sponsor:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Standard BioTools Inc.</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">c/o Chief Human Resources Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50 Milk Street, 10th Floor</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Boston, MA 02109</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification Numbers:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EIN: 77-0513190</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PLAN: 502</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Year</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Company's fiscal year</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Administrator</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Human Capital Committee</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attention:</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Administrator of the</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. 2026 Change of Control and</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severance Plan</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50 Milk Street, 10th Floor</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Boston MA, 02109</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">650-266-6000</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:2%;text-indent:-34.259%;padding-left:24.667%;font-size:10pt;margin-top:11.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:63.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34.921%;box-sizing:content-box;"></td>
     <td style="width:65.079%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Agent for Service of</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Legal Process:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Standard BioTools Inc.</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attention: Chief Human Resources Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026 Change of Control and Severance Plan</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50 Milk Street, 10th Floor</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">650-266-6000</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Service of process also may be made upon the Administrator</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Plan:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severance Plan/Employee Welfare Benefit Plan</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Costs:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The cost of the Plan is paid by the Employer</font></p></td>
    </tr>
   </table><p style="margin-left:12.667%;font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6%;font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement of ERISA Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As a Participant under the Plan, you have certain rights and protections under ERISA:</font></p><div class="item-list-element-wrapper" style="margin-left:16%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:3.175%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may examine (without charge) all Plan documents, including any amendments and copies of all documents filed with the U.S. Department of Labor. These documents are available for your review in the Company&#x2019;s Human Resources Department.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:16%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:3.175%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may obtain copies of all Plan documents and other Plan information upon written request to the Administrator. A reasonable charge may be made for such copies.</font></div></div><p style="text-indent:6%;font-size:10pt;margin-top:11.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to creating rights for Participants, ERISA imposes duties upon the people who are responsible for the operation of the Plan. The people who operate the Plan (called &#x201c;fiduciaries&#x201d;) have a duty to do so prudently and in the interests of you and the other Participants. No one, including the Company or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a benefit under the Plan or exercising your rights under ERISA. If your claim for payments or benefits under the Plan is denied, in whole or in part, you must receive a written explanation of the reason for the denial. You have the right to have the denial of your claim reviewed. (The claim review procedure is explained in Section 16 above.)</font></p><p style="text-indent:6%;font-size:10pt;margin-top:11.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ERISA, there are steps you can take to enforce the above rights. For example, if you request materials and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Administrator to provide the materials and to pay you up to $110 a day until you receive the materials, unless the materials were not sent due to reasons beyond the control of the Administrator. If you have a claim which is denied or ignored, in whole or in part, you may file suit in a federal court. If it should happen that you are discriminated</font></p><p style="font-size:10pt;margin-top:14.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court.</font></p><p style="text-indent:6%;font-size:10pt;margin-top:11.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In any case, the court will decide who will pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds that your claim is frivolous.</font></p><p style="text-indent:6%;font-size:10pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:36pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you have any questions regarding the Plan, please contact the Administrator. If you have any questions about this statement or about your rights under ERISA, you may contact the nearest area office of the Employee Benefits Security Administration (formerly the Pension and Welfare Benefits Administration), U.S. Department of Labor, listed in your telephone directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W. Washington, D.C. 20210. You also may obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> </font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:14.7pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Leadership Team Members <br>Appendix A</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:17.35pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. 2026 Change of Control and <br>Severance Plan Participation Agreement</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is pleased to inform you that you have been selected to participate in the Company&#x2019;s 2026 Change of Control and Severance Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as a Participant.</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:11.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:10.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement.</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:13.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of &#x201c;Good Reason&#x201d;</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:10.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of one or more of the following events effected without your prior consent, provided you terminate your employment with the Company within six months following the initial existence of the &#x201c;Good Reason&#x201d; condition (discussed below): (i) the assignment to you of any duties or the reduction of your then-current duties, either of which results in a material diminution in your then-current position or responsibilities with the Company including, without limitation, any negative change in reporting hierarchy involving you or the person to whom you directly report; (ii) a material reduction by the Company in your then- current base salary; (iii) a material change in the geographic location at which you must perform services (for purposes of this Participation Agreement, your relocation to a facility or a location more than 50 miles from your then-present location shall be considered a material change in geographic location); or (iv) any material breach by the Company of any material provision of this Participation Agreement. You will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#x201c;Good Reason&#x201d; within 90 days of the initial existence of the grounds for &#x201c;Good Reason&#x201d; and a Company cure period of 30 days following the date of such notice.</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:13.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-COC Involuntary Termination</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:11.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, outside of the Change of Control Period, you incur a Non-COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:6.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="margin-left:6%;text-indent:-7.634%;padding-left:6.667%;font-size:10pt;margin-top:4.4pt;font-family:Times New Roman;margin-bottom:30pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An aggregate amount equal to 100% of your annual base salary in effect as of the date of your Non-COC Involuntary Termination paid in equal installments over a period of 12 months following your termination date.</font></p><p style="margin-left:6%;text-indent:-7.634%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to the Non-COC Involuntary Termination), multiplied by (ii) a fraction, the numerator of which is the number of days worked by you during the year in which the Non-COC Involuntary Termination occurs and the denominator of which is 365.</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:11.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:6%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA for a period of 12 months following your termination of employment. Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA as determined by the Administrator in its sole discretion.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:6%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 4.3 of the Plan.</font></div></div><p style="font-size:10pt;margin-top:6.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COC Involuntary Termination</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:11.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><p style="font-size:10pt;margin-top:6.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="margin-left:6%;display:flex;margin-top:4.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:7.092553191489362%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump-sum payment equal to 150% of the sum of (x) your annual base salary (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), plus (y) the greater of (A) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater) or (B) the average of the annual bonuses actually paid to you with respect to the three fiscal years preceding the year in which your COC Involuntary Termination occurs; provided, however, that if the annual bonus with respect to the most recently preceding fiscal year has not yet been paid, your annual target bonus will be used as the bonus for that year in calculating the average. For the avoidance of doubt, if you incurred a termination prior to a Change of Control that qualifies as a COC Involuntary Termination, then you will be entitled to a lump-sum payment of the amount calculated under the preceding sentence, less amounts already paid as cash Severance Benefits for a Non-COC Involuntary Termination.</font></div></div><div class="item-list-element-wrapper" style="margin-left:6%;display:flex;margin-top:11.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:36pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:7.092553191489362%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), multiplied by (ii) a fraction, the numerator of which is the number of days worked by you during the year in which the COC Involuntary Termination occurs and the denominator of which is 365.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;justify-content:flex-start;min-width:2.4%;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA for a period of 18 months following your termination of employment. Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA determined by the Administrator in its sole discretion.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;justify-content:flex-start;min-width:2.4%;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Award Vesting Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. 100% of your then-outstanding and unvested Equity Awards will become vested in full. If, however, an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless expressly otherwise provided in the applicable Equity Award agreement, the Equity Award will vest as to 100% of the &#x201c;Baseline Number of Restricted Stock Units&#x201d; or &#x201c;Baseline Number of Performance Units&#x201d; (as defined in the Company&#x2019;s grant agreements) or the equivalent measure of the number of units or shares that vest at 100% of target levels of achievement under the relevant Equity Award. Except otherwise provided in the applicable Equity Award agreement, shares owed upon such vesting (and exercise if applicable) of Equity Awards will issued to you as promptly as practicable and no more than 30 days after they become issuable (whether through the vesting acceleration alone or upon an exercise of options following such vesting acceleration). Notwithstanding the foregoing, to the extent that the payment or settlement of an Equity Award is subject to Section 409A, the Equity Award will be paid or settled in a manner that will meet the requirements of Section 409A such that the payment or settlement will not be subject to the additional tax or interest applicable under Section 409A.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11.5pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;justify-content:flex-start;min-width:2.4%;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 5.4 of the Plan.</font></div></div><p style="margin-left:1.333%;font-size:10pt;margin-top:13.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Benefits</font></p><div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:11.4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the foregoing benefits, in addition to the Plan benefits described above, if, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, the Company will reimburse your reasonable attorneys&#x2019; fees incurred in connection with the review of the Release and any related separation agreements and documents, up to $5,000.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.333%;margin-top:11.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:36pt;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:3.2432322863774115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the Non-COC Involuntary Termination benefits described above, if you incur a Non-COC Involuntary Termination on or prior to August 27, 2026, then subject to the terms and condition of the Plan, you will receive the equity award vesting acceleration as described under paragraph 3 above under the heading COC Involuntary Termination.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> </font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:17.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Provisions</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:11.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, any severance payments provided for herein that are based on annual base salary (and any reduction to base salary constituting &#x201c;Good Reason&#x201d;) shall be calculated without giving effect to any temporary reduction in base salary imposed by the Company or agreed to by you in connection with any global pandemic or comparable global or U.S. emergency that threatens the Company&#x2019;s economic position.</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:11.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period set forth in the Plan.</font></p><p style="margin-left:0.667%;font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:36pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Remainder of This Page Intentionally Left Blank]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that: (1) you have received a copy of the 2026 Change of Control and Severance Plan and Summary Plan Description; (2) you have carefully read this Participation Agreement and the 2026 Change of Control and Severance Plan and Summary Plan Description; (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successors; and (4) participation in the Plan and this Participation Agreement replaces in its entirety any severance and/or change of control provisions set forth in any offer letter, employment agreement and/or Equity Award agreement, including, but not limited to, the Prior Plan.</font></p><p style="font-size:10pt;margin-top:15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"></td>
     <td style="width:13%;box-sizing:content-box;"></td>
     <td style="width:45%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">STANDARD BIOTOOLS INC.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PARTICIPANT</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2.3pt;margin-right:0.037%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:33.7pt;font-family:Times New Roman;margin-bottom:36pt;margin-right:2%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment: Standard BioTools Inc. 2026 Change of Control and Severance Plan and Summary Plan Description</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature Page to the Participation Agreement]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>lab-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-28T15:37:47.6703+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Leadership Team Members</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. 2026 Change of Control and Severance Plan</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participation Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is pleased to inform you that you have been selected to participate in the Company&#x2019;s 2026 Change of Control and Severance Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as a Participant.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of &#x201c;Good Reason&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of one or more of the following events effected without your prior consent, provided you terminate your employment with the Company within six months following the initial existence of the &#x201c;Good Reason&#x201d; condition (discussed below): (i) the assignment to you of any duties or the reduction of your then-current duties, either of which results in a material diminution in your then-current position or responsibilities with the Company including, without limitation, any negative change in reporting hierarchy involving you or the person to whom you directly report; (ii) a material reduction by the Company in your then- current base salary; (iii) a material change in the geographic location at which you must perform services (for purposes of this Participation Agreement, your relocation to a facility or a location more than 50 miles from your then-present location shall be considered a material change in geographic location); or (iv) any material breach by the Company of any material provision of this Participation Agreement. You will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#x201c;Good Reason&#x201d; within 90 days of the initial existence of the grounds for &#x201c;Good Reason&#x201d; and a Company cure period of 30 days following the date of such notice.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-COC Involuntary Termination</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, outside of the Change of Control Period, you incur a Non-COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An aggregate amount equal to 100% of your annual base salary in effect as of the date of your Non-COC Involuntary Termination paid in equal installments over a period of 12 months following your termination date.</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to the Non-COC Involuntary Termination), multiplied by (ii) a fraction, the numerator of which is the number of days worked by you during the year in which the Non-COC Involuntary Termination occurs and the denominator of which is 365.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.333%;text-align:right;margin-left:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA for a period of 12 months following your termination of employment. Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA as determined by the Administrator in its sole discretion.</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 4.3 of the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COC Involuntary Termination</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump-sum payment equal to 150% of the sum of (x) your annual base salary (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), plus (y) the greater of (A) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater) or (B) the average of the annual bonuses actually paid to you with respect to the three fiscal years preceding the year in which your COC Involuntary Termination occurs; provided, however, that if the annual bonus with respect to the most recently preceding fiscal year has not yet been paid, your annual target bonus will be used as the bonus for that year in calculating the average. For the avoidance of doubt, if you incurred a termination prior to a Change of Control that qualifies as a COC Involuntary Termination, then you will be entitled to a lump-sum payment of the amount calculated under the preceding sentence, less amounts already paid as cash Severance Benefits for a Non-COC Involuntary Termination.</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), multiplied by (ii) a fraction, the numerator of which is the number of days worked by you during the year in which the COC Involuntary Termination occurs and the denominator of which is 365.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA for a period of 18 months following your termination of employment. Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA determined by the Administrator in its sole discretion.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Award Vesting Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. 100% of your then-outstanding and unvested Equity Awards will become vested in full. If, however, an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless expressly otherwise provided in the applicable Equity Award agreement, the Equity Award will vest as to 100% of the &#x201c;Baseline Number of Restricted Stock Units&#x201d; or &#x201c;Baseline Number of Performance Units&#x201d; (as defined in the Company&#x2019;s grant agreements) or the equivalent measure of the number of units or shares that vest at 100% of target levels of achievement under the relevant Equity Award. Except otherwise provided in the applicable Equity Award agreement, shares owed upon such vesting (and exercise if applicable) of Equity Awards will issued to you as promptly as practicable and no more than 30 days after they become issuable (whether through the vesting acceleration alone or upon an exercise of options following such vesting acceleration). Notwithstanding the foregoing, to the extent that the payment or settlement of an Equity Award is subject to Section 409A, the Equity Award will be paid or settled in a manner that will meet the requirements of Section 409A such that the payment or settlement will not be subject to the additional tax or interest applicable under Section 409A.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.333%;text-align:right;margin-left:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 5.4 of the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Benefits</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the foregoing benefits, in addition to the Plan benefits described above, if, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, the Company will reimburse your reasonable attorneys&#x2019; fees incurred in connection with the review of the Release and any related separation agreements and documents, up to $5,000.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the Non-COC Involuntary Termination benefits described above, if you incur a Non-COC Involuntary Termination on or prior to August 27, 2026, then subject to the terms and condition of the Plan, you will receive the equity award vesting acceleration as described under paragraph 3 above under the heading COC Involuntary Termination.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Provisions</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, any severance payments provided for herein that are based on annual base salary (and any reduction to base salary constituting &#x201c;Good Reason&#x201d;) shall be calculated without giving effect to any temporary reduction in base salary imposed by the Company or agreed to by you in connection with any global pandemic or comparable global or U.S. emergency that threatens the Company&#x2019;s economic position.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period set forth in the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Remainder of This Page Intentionally Left Blank]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"><br> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that: (1) you have received a copy of the 2026 Change of Control and Severance Plan and Summary Plan Description; (2) you have carefully read this Participation Agreement and the 2026 Change of Control and Severance Plan and Summary Plan Description; (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors; and (4) participation in the Plan and this Participation Agreement replaces in its entirety any severance and/or change of control provisions set forth in any offer letter, employment agreement and/or Equity Award agreement, including, but not limited to, the Prior Plan.</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"></td>
     <td style="width:13%;box-sizing:content-box;"></td>
     <td style="width:45%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">STANDARD BIOTOOLS INC.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PARTICIPANT</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Egholm</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alex Kim</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Egholm</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alex Kim</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CFO</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.333%;text-align:right;margin-left:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"></td>
     <td style="width:13%;box-sizing:content-box;"></td>
     <td style="width:45%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 26, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 27, 2026</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment: Standard BioTools Inc. 2026 Change of Control and Severance Plan and Summary Plan Description</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>lab-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-28T15:37:47.6639+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.333%;text-align:right;margin-left:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Leadership Team Members</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. 2026 Change of Control and Severance Plan</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participation Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is pleased to inform you that you have been selected to participate in the Company&#x2019;s 2026 Change of Control and Severance Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as a Participant.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of &#x201c;Good Reason&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of one or more of the following events effected without your prior consent, provided you terminate your employment with the Company within six months following the initial existence of the &#x201c;Good Reason&#x201d; condition (discussed below): (i) the assignment to you of any duties or the reduction of your then-current duties, either of which results in a material diminution in your then-current position or responsibilities with the Company including, without limitation, any negative change in reporting hierarchy involving you or the person to whom you directly report; (ii) a material reduction by the Company in your then- current base salary; (iii) a material change in the geographic location at which you must perform services (for purposes of this Participation Agreement, your relocation to a facility or a location more than 50 miles from your then-present location shall be considered a material change in geographic location); or (iv) any material breach by the Company of any material provision of this Participation Agreement. You will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#x201c;Good Reason&#x201d; within 90 days of the initial existence of the grounds for &#x201c;Good Reason&#x201d; and a Company cure period of 30 days following the date of such notice.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-COC Involuntary Termination</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, outside of the Change of Control Period, you incur a Non-COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An aggregate amount equal to 100% of your annual base salary in effect as of the date of your Non-COC Involuntary Termination paid in equal installments over a period of 12 months following your termination date.</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to the Non-COC Involuntary Termination), multiplied by (ii) a fraction, the numerator of which is the number of days worked by you during the year in which the Non-COC Involuntary Termination occurs and the denominator of which is 365.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.333%;text-align:right;margin-left:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA for a period of 12 months following your termination of employment. Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA as determined by the Administrator in its sole discretion.</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 4.3 of the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COC Involuntary Termination</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump-sum payment equal to 150% of the sum of (x) your annual base salary (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), plus (y) the greater of (A) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater) or (B) the average of the annual bonuses actually paid to you with respect to the three fiscal years preceding the year in which your COC Involuntary Termination occurs; provided, however, that if the annual bonus with respect to the most recently preceding fiscal year has not yet been paid, your annual target bonus will be used as the bonus for that year in calculating the average. For the avoidance of doubt, if you incurred a termination prior to a Change of Control that qualifies as a COC Involuntary Termination, then you will be entitled to a lump-sum payment of the amount calculated under the preceding sentence, less amounts already paid as cash Severance Benefits for a Non-COC Involuntary Termination.</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), multiplied by (ii) a fraction, the numerator of which is the number of days worked by you during the year in which the COC Involuntary Termination occurs and the denominator of which is 365.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA for a period of 18 months following your termination of employment. Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph will be a regional equivalent to COBRA determined by the Administrator in its sole discretion.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Award Vesting Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. 100% of your then-outstanding and unvested Equity Awards will become vested in full. If, however, an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless expressly otherwise provided in the applicable Equity Award agreement, the Equity Award will vest as to 100% of the &#x201c;Baseline Number of Restricted Stock Units&#x201d; or &#x201c;Baseline Number of Performance Units&#x201d; (as defined in the Company&#x2019;s grant agreements) or the equivalent measure of the number of units or shares that vest at 100% of target levels of achievement under the relevant Equity Award. Except otherwise provided in the applicable Equity Award agreement, shares owed upon such vesting (and exercise if applicable) of Equity Awards will issued to you as promptly as practicable and no more than 30 days after they become issuable (whether through the vesting acceleration alone or upon an exercise of options following such vesting acceleration). Notwithstanding the foregoing, to the extent that the payment or settlement of an Equity Award is subject to Section 409A, the Equity Award will be paid or settled in a manner that will meet the requirements of Section 409A such that the payment or settlement will not be subject to the additional tax or interest applicable under Section 409A.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.333%;text-align:right;margin-left:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 5.4 of the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Benefits</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the foregoing benefits, in addition to the Plan benefits described above, if, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, the Company will reimburse your reasonable attorneys&#x2019; fees incurred in connection with the review of the Release and any related separation agreements and documents, up to $5,000.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the Non-COC Involuntary Termination benefits described above, if you incur a Non-COC Involuntary Termination on or prior to August 27, 2026, then subject to the terms and condition of the Plan, you will receive the equity award vesting acceleration as described under paragraph 3 above under the heading COC Involuntary Termination.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Provisions</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, any severance payments provided for herein that are based on annual base salary (and any reduction to base salary constituting &#x201c;Good Reason&#x201d;) shall be calculated without giving effect to any temporary reduction in base salary imposed by the Company or agreed to by you in connection with any global pandemic or comparable global or U.S. emergency that threatens the Company&#x2019;s economic position.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period set forth in the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Remainder of This Page Intentionally Left Blank]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"><br> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that: (1) you have received a copy of the 2026 Change of Control and Severance Plan and Summary Plan Description; (2) you have carefully read this Participation Agreement and the 2026 Change of Control and Severance Plan and Summary Plan Description; (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors; and (4) participation in the Plan and this Participation Agreement replaces in its entirety any severance and/or change of control provisions set forth in any offer letter, employment agreement and/or Equity Award agreement, including, but not limited to, the Prior Plan.</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"></td>
     <td style="width:13%;box-sizing:content-box;"></td>
     <td style="width:45%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">STANDARD BIOTOOLS INC.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PARTICIPANT</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Egholm</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Sean Mackay</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Egholm</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sean Mackay</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Business Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.333%;text-align:right;margin-left:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"></td>
     <td style="width:13%;box-sizing:content-box;"></td>
     <td style="width:45%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 26, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 27, 2026</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment: Standard BioTools Inc. 2026 Change of Control and Severance Plan and Summary Plan Description</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>lab-ex10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-28T15:37:47.6663+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.4</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1.22in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 10.4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">STANDARD BIOTOOLS INC.</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">2023 CHANGE OF CONTROL AND SEVERANCE PLAN</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">AND SUMMARY PLAN DESCRIPTION</font></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Adopted August 4, 2023 (as amended and restated May 21, 2026)</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:9.2pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Introduction</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. The purpose of this Standard BioTools Inc. 2023 Change of Control and Severance Plan (as amended and restated and as may be further amended from time to time), or Plan (as defined in Section 2 below), is to provide assurances of specified benefits to certain employees of the Company whose employment is subject to being involuntarily terminated other than for death, Disability, or Cause or voluntarily terminated for Good Reason under the circumstances described herein. This Plan is an &#x201c;employee welfare benefit plan,&#x201d; as defined in Section 3(1) of the U.S. Employee Retirement Income Security Act of 1974, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;). This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan. The Plan, as originally adopted, replaced that certain Fluidigm Corporation Change of Control and Severance Plan and Summary Plan Description adopted by the Compensation Committee of Fluidigm Corporation on August 4, 2020 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Prior Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), and this Plan, as amended and restated and set forth in this document, is a replacement for the Plan adopted by the Compensation Committee of the Company on August 4, 2023. The Prior Plan expired according to its terms and was not renewed. By becoming a Participant under this Plan (and immediately upon execution of the Participation Agreement), the Participant expressly acknowledges that Participant will cease being entitled to any benefits under the Plan as originally adopted and the corresponding Participation Agreement and will become subject to the terms of the Plan, as amended and restated, effective as of the Effective Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.55pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Important Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. The following words and phrases, when the initial letter of the term is capitalized, will have the meanings set forth in this Section 2, unless a different meaning is plainly required by the context:</font></div></div><p style="text-indent:12.667%;font-size:10pt;margin-top:5.7pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.1.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the Human Capital Committee whose members have been delegated duty by the Board to act as the Administrator of the Plan within the meaning of Section 3(16)(A) of ERISA, or another duly constituted committee that has been delegated such duty by the Board, or any person to whom the Board has delegated any authority or responsibility with respect to the Plan pursuant to Section 12, but only to the extent of such delegation.</font></p><p style="margin-left:12.667%;font-size:10pt;margin-top:1.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.2.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.3.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; exists upon (i) a Participant&#x2019;s conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (ii) a Participant&#x2019;s (a) engagement in material dishonesty, willful misconduct, or gross negligence&#x2014;in each case in connection with the Participant&#x2019;s position at the Company; (b) breach of any confidentiality, invention assignment, non-disclosure, or non-solicitation agreement entered into between the Company and the Participant; (c) material violation of a written Company policy or procedure that has been provided to the Participant, which violation causes substantial injury to the Company; or (d) willful refusal to perform the Participant&#x2019;s assigned duties to the Company,</font></p><p style="font-size:10pt;margin-top:28.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.53in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:14.8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">following written notice of such refusal by the Company and a period of fifteen (15) days to cure the same and the Participant&#x2019;s failure to cure during such time period. No act or omission shall be considered &#x201c;willful&#x201d; if such act or omission was done, or not done, in the reasonable, good-faith belief that such act or omission was in the best interests of the Company or upon the advice of counsel to the Company.</font></p><p style="margin-left:12.667%;font-size:10pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">2.4.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of any of the following events:</font></p><p style="text-indent:18.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">2.4.1. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Change in Ownership of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. A change in the ownership of the Company which occurs on the date that any &#x201c;Person&#x201d; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company pursuant to a transaction or a series of related transactions; provided, however, that for purposes of this subsection 2.4.1, the acquisition of additional stock by any one Person, who is considered to own more than 50% of the total voting power of the stock of the Company will not be considered a Change of Control; or</font></p><p style="text-indent:18.667%;font-size:10pt;margin-top:5.3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">2.4.2. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Change in Effective Control of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. A change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this subsection 2.4.2, if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change of Control; or</font></p><p style="text-indent:18.667%;font-size:10pt;margin-top:5.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">2.4.3. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Merger or Sale of the Company&#x2019;s Assets</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.	A merger or <br>consolidation of the Company or any of its subsidiaries whether or not approved by the Board of Directors, or the sale or disposition by the Company of all or substantially all of the Company&#x2019;s assets in a transaction requiring shareholder approval; provided, however, that for purposes of this subsection 2.4.3, the following will not constitute a Change of Control: (A) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such entity) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B) a transfer of assets by the Company to: (1) an entity that is controlled by the Company&#x2019;s stockholders immediately after the transfer, (2) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#x2019;s stock, (3) an entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (4) a Person, that owns, directly or indirectly, 50% or more of the total value or voting power of all the outstanding stock of the Company, or (5) an entity, at least 50% of the total value or voting power of which is owned, directly or indirectly, by a Person described in subsection 2.4.3(B)(4).</font></p><p style="font-size:10pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, a transaction will not be deemed a Change of Control unless the transaction qualifies as a change in control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations</font></p><p style="font-size:10pt;margin-top:22.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:13.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.</font></p><p style="font-size:10pt;margin-top:5.7pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, a transaction will not constitute a Change of Control if: (i) its sole purpose is to change the state of the Company&#x2019;s incorporation, (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transaction or (iii) its sole purpose is to obtain funding for the Company in a financing that is approved by the Board.</font></p><p style="font-size:10pt;margin-top:5.85pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Notwithstanding any of the foregoing, however</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">, in any circumstance or transaction in which compensation or benefits paid under this Plan would result in imposition of an additional tax under Section 409A of the Code if the foregoing definition of &#x201c;Change of Control&#x201d; were to apply, but would not result in the imposition of any additional tax if the term &#x201c;Change of Control&#x201d; were defined herein to mean a &#x201c;change in control event&#x201d; within the meaning of Treasury Regulation Section 1.409A-3(i)(5), then &#x201c;Change of Control&#x201d; shall mean a &#x201c;change in control event&#x201d; within the meaning of Treasury Regulation Section 1.409A-3(i)(5), but only to the extent necessary to prevent such compensation from becoming subject to an additional tax under Section 409A.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:6.85pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.5.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Change of Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the time period beginning three (3) <br>months prior to a Change of Control and ending on the date that is twelve (12) months following the Change of Control.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.6.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended. Reference <br>to a specific section of the Code or regulation thereunder shall include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.7.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means Standard BioTools Inc. and any successor that assumes <br>the obligations of the Company under the Plan by way of merger, acquisition, consolidation or other transaction.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.8.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means that Participant has been unable to perform his or her <br>Company duties as the result of Participant&#x2019;s incapacity due to physical or mental illness, and such inability, at least twenty-six (26) weeks after its commencement, is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to Participant or Participant&#x2019;s legal representative (such agreement as to acceptability not to be unreasonably withheld). Termination resulting from Disability may only be effected after at least 30 days&#x2019; written notice by the Company of its intention to terminate Participant&#x2019;s employment. In the event that Participant resumes the performance of substantially all of his or her duties hereunder before the termination of employment becomes effective, the notice of intent to terminate will automatically be deemed to have been revoked.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.85pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.9.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means May 21, 2026, which is the date this Plan was <br>deemed effective by the Human Capital Committee of the Board.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.10.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as <br>amended.</font></p><p style="font-size:10pt;margin-top:32.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:12.667%;font-size:10pt;margin-top:15.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.11.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Equity Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means a Participant&#x2019;s outstanding stock options, stock <br>appreciation rights, restricted stock, restricted stock units, performance shares, performance stock units, and any other Company equity compensation awards.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.12.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Participant&#x2019;s Participation <br>Agreement.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.7pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.13.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Involuntary Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means a Non-COC Involuntary Termination or <br>a COC Involuntary Termination, in each case, under the circumstances described in Section 4 or Section 5, as applicable.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.14.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means an employee of the Company or of any parent or <br>subsidiary of the Company who (a) has been designated by the Administrator to participate in the Plan and (b) has timely and properly executed and delivered a Participation Agreement to the Company.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.15.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Participation Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the individual agreement (as will be <br>provided in separate cover as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">) provided by the Administrator to a Participant under the Plan, which has been signed and accepted by the Participant.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.65pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.16.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the Standard BioTools Inc. 2023 Change of Control and <br>Severance Plan as amended and restated and set forth in this document and as hereafter amended from time to time.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.17.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means Section 409A of the Code and the final regulations <br>and any guidance promulgated thereunder.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:6.15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.18.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Section 409A Limit</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means two (2) times the lesser of: (i) the Participant&#x2019;s <br>annualized compensation based upon the annual rate of pay paid to the Participant during the taxable year preceding the taxable year of the Participant&#x2019;s termination of employment as determined under, and with such adjustments as are set forth in, Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which the Participant&#x2019;s employment is terminated.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	2.19.	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the compensation and other benefits that the <br>Participant will be provided in the circumstances described in Section 4 or Section 5 of the Plan, as applicable.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.6pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Eligibility for Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. An individual is eligible for Severance Benefits under the Plan, as described in Section 4 or Section 5, as applicable, only if he or she experiences an Involuntary Termination.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.65pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Involuntary Termination Outside the Change of Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. If, outside of the Change of Control Period, the Company (or any parent or subsidiary of the Company) terminates the Participant&#x2019;s employment for a reason other than for Cause, the Participant&#x2019;s death or Disability (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Non-COC Involuntary Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), subject to the Participant&#x2019;s compliance with Section 7, the Participant will receive the following Severance Benefits:</font></div></div><p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:14.75pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	4.1.	Cash Severance Benefits. Continued payments of cash severance and/or <br>a bonus payment for the periods set forth in the Participant&#x2019;s Participation Agreement;</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:4.95pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	4.2.	Continued Medical Benefits. If the Participant and any spouse and/or <br>other dependents of the Participant (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Family Members</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) have coverage on the date of the Participant&#x2019;s Involuntary Termination under a group health plan sponsored by the Company, the Company will pay on behalf of Participant the total applicable premium cost for continued group health plan coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">COBRA</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) during the period of time following the Participant&#x2019;s employment termination, as set forth in the Participant&#x2019;s Participation Agreement, provided that the Participant validly elects and is eligible to continue coverage under COBRA for the Participant and any such Family Members; and</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	4.3.	Outplacement Services. Reasonable outplacement services in accordance <br>with any applicable Company policy in effect as of the Participant&#x2019;s Non-COC Involuntary Termination (or if no such policy is in effect, as determined by the Company, in its sole discretion).</font></p><p style="text-indent:6%;font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">5.	Involuntary Termination During the Change of Control Period. If, during the <br>Change of Control Period, (i) a Participant terminates his or her employment with the Company (or any parent or subsidiary of the Company) for Good Reason, or (ii) the Company (or any parent or subsidiary of the Company) terminates the Participant&#x2019;s employment for a reason other than Cause or the Participant&#x2019;s death or Disability (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">COC Involuntary Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), then, in each case, subject to the Participant&#x2019;s compliance with Section 7, the Participant will receive the following Severance Benefits:</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	5.1.	Cash Severance Benefits. A lump-sum payment of cash severance and/or <br>bonus equal to the amount set forth in the Participant&#x2019;s Participation Agreement;</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	5.2.	Equity Award Vesting Acceleration Benefit. The Participant&#x2019;s Equity <br>Awards will accelerate and vest to the amount set forth in the Participant&#x2019;s Participation Agreement, as applicable;</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	5.3.	Continued Medical Benefits. If the Participant, and any Family Member(s) <br>has/have coverage on the date of the Participant&#x2019;s Involuntary Termination under a group health plan sponsored by the Company, the Company will pay on behalf of Participant the total applicable premium cost for continued group health plan coverage under the COBRA during the period of time following the Participant&#x2019;s employment termination, as set forth in the Participant&#x2019;s Participation Agreement, provided that the Participant validly elects and is eligible to continue coverage under COBRA for the Participant and his or her Family Members; and</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	5.4.	Outplacement Services. Reasonable outplacement services in accordance <br>with any applicable Company policy in effect as of the Participant&#x2019;s COC Involuntary Termination (or if no such policy is in effect, as determined by the Company, in its sole discretion); provided, however, that such outplacement services shall be in no case less than the outplacement services provided under any applicable Company policy in effect immediately prior to the applicable Change of Control.</font></p><p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6%;font-size:10pt;margin-top:15.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">6.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Limitation on Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. In the event that the severance and other benefits provided for in this Plan or otherwise (&#x201c;280G Payments&#x201d;) payable to a Participant (i) constitute &#x201c;parachute payments&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this Section 6, would be subject to the excise tax imposed by Section 4999 of the Code, then the 280G Payments will be either:</font></p><p style="margin-left:12%;font-size:10pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">6.1.	delivered in full, or</font></p><p style="text-indent:12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">6.2.	delivered as to such lesser extent as would result in no portion of such benefits being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by the Participant on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999. If a reduction in severance and other benefits constituting &#x201c;parachute payments&#x201d; is necessary so that benefits are delivered to a lesser extent, reduction will occur in the following order: (a) cancellation of awards granted &#x201c;contingent on a change in ownership or control&#x201d; (within the meaning of Code Section 280G); (b) a pro rata reduction of (i) cash payments that are subject to Section 409A as deferred compensation and (ii) cash payments not subject to Section 409A; (c) a pro rata reduction of (i) employee benefits that are subject to Section 409A as deferred compensation and (ii) employee benefits not subject to Section 409A; and (d) a pro rata cancellation of (i) accelerated vesting equity awards that are subject to Section 409A as deferred compensation and (ii) equity awards not subject to Section 409A. In the event that acceleration of vesting of equity awards is to be cancelled, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Participant&#x2019;s equity awards. Notwithstanding the foregoing, to the extent the Company submits any payment or benefit payable to the Participant under this Plan or otherwise to the Company&#x2019;s stockholders for approval in accordance with Treasury Regulation Section 1.280G-1 Q&amp;A 7, the foregoing provisions shall not apply following such submission and such payments and benefits will be treated in accordance with the results of such vote, except that any reduction in, or waiver of, such payments or benefits required by such vote will be applied without any application of discretion by the Participant and in the order prescribed by this Section 6.</font></p><p style="font-size:10pt;margin-top:6.15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 6 will be made in writing by the Company&#x2019;s independent public accountants immediately prior to the Change of Control or such other person or entity to which the parties mutually agree (the &#x201c;Firm&#x201d;), whose determination will be conclusive and binding upon the Participant and the Company. For purposes of making the calculations required by this Section 6 the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Participant and the Company will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section 6. The Company will bear all costs the Firm may incur in connection with any calculations contemplated by this Section 6.</font></p><p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10.6pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Conditions to Receipt of Severance</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:12.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	7.1.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Release Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. As a condition to receiving the Severance Benefits <br>under this Plan, each Participant will be required to sign and not revoke a separation and release of claims agreement in substantially the form attached this Plan as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Appendix B</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;). In all cases, the Release must become effective and irrevocable no later than the 60th day following the Participant&#x2019;s Involuntary Termination (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Release Deadline Date</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;). If the Release does not become effective and irrevocable by the Release Deadline Date, the Participant will forfeit any right to the Severance Benefits. In no event will the Severance Benefits be paid or provided until the Release becomes effective and irrevocable.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.7pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	7.2.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Other Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. A Participant&#x2019;s receipt of Severance Benefits will be <br>subject to the Participant continuing to comply with the provisions of this Section 7 and the terms of any confidentiality, proprietary information and inventions agreement and such other appropriate agreement between the Participant and the Company. Severance Benefits under this Plan will terminate immediately for a Participant if the Participant, at any time, violates any such agreement and/or the provisions of this Section 7.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.35pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Timing of Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. Provided that the Release becomes effective and irrevocable by the Release Deadline Date and subject to Section 10, the Severance Benefits will be paid (or in the case of Severance Benefits scheduled to be paid installments, will commence) on the first Company payroll date following the Release Deadline Date (such payment date, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Severance Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), and any severance payments or benefits otherwise payable to the Participant during the period immediately following the Participant&#x2019;s termination of employment with the Company through the Severance Start Date will be paid in a lump sum to the Participant on the Severance Start Date, with any remaining payments to be made as provided in this Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.75pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Exclusive Benefit</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. The benefits provided under this Plan shall be the exclusive benefit for a Participant related to termination of employment and/or change in control and shall supersede and replace any severance and/or change in control benefits set forth in any offer letter, employment agreement and/or severance agreement, including without limitation the Prior Plan and the Plan as originally adopted. For the avoidance of doubt, if a Participant was otherwise eligible to participate in any other Company severance plan (whether or not subject to ERISA), then participation in this Plan will supersede and replace eligibility in such other plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:1.2pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:12.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	10.1.	Notwithstanding anything to the contrary in this Plan, no severance <br>payments or benefits to be paid or provided to a Participant, if any, under this Plan that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) will be paid or provided until the Participant has a &#x201c;separation from service&#x201d; within the meaning of Section 409A. Similarly, no severance payable to a Participant, if any, under this Plan that otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A 1(b)(9) will be payable until the Participant has a &#x201c;separation from service&#x201d; within the meaning of Section 409A.</font></p><p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:14.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	10.2.	It is intended that none of the severance payments or benefits under this <br>Plan will constitute Deferred Payments but rather will be exempt from Section 409A as a payment that would fall within the &#x201c;short-term deferral period&#x201d; as described in Section 10.3 below or resulting from an involuntary separation from service as described in Section 10.4 below. In no event will a Participant have discretion to determine the taxable year of payment of any Deferred Payment.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">10.3. Notwithstanding anything to the contrary in this Plan or in any Participation Agreement, if a Participant is a &#x201c;specified employee&#x201d; within the meaning of Section 409A at the time of the Participant&#x2019;s separation from service (other than due to death), then the Deferred Payments, if any, that are payable within the first six (6) months following the Participant&#x2019;s separation from service, will become payable on the date six (6) months and one (1) day following the date of the Participant&#x2019;s separation from service. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, in the event of the Participant&#x2019;s death following the Participant&#x2019;s separation from service, but before the six-month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of the Participant&#x2019;s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Plan is intended to constitute a separate payment under Section 1.409A-2(b)(2) of the Treasury Regulations.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	10.4.	Any amount paid under this Plan that satisfies the requirements of the <br>&#x201c;short-term deferral&#x201d; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of Section 10 above.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	10.5.	Any amount paid under this Plan that qualifies as a payment made as a <br>result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Payments for purposes of Section 10 above.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">10.6. The foregoing provisions are intended to comply with or be exempt from the requirements of Section 409A so that none of the payments and benefits to be provided under the Plan will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply or be exempt. Notwithstanding anything to the contrary in the Plan, including but not limited to Sections 12 and 15, the Company reserves the right to amend the Plan as it deems necessary or advisable, in its sole discretion and without the consent of the Participants, to comply with Section 409A or to avoid income recognition under Section 409A prior to the actual payment of benefits under the Plan or imposition of any additional tax. In no event will the Company reimburse a Participant for any taxes that may be imposed on the Participant as result of Section 409A.</font></p><p style="text-indent:6%;font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Withholdings</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. The Company will withhold from any payments or benefits under <br>the Plan all applicable U.S. federal, state, local and non-U.S. taxes required to be withheld and any other required payroll deductions.</font></p><p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:15.3pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">12.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. The Plan will be administered and interpreted by the Administrator (in its sole discretion). The Administrator is the &#x201c;named fiduciary&#x201d; of the Plan for purposes of ERISA and will be subject to the fiduciary standards of ERISA when acting in such capacity. Any decision made or other action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document, will be conclusive and binding on all persons and be given the maximum possible deference allowed by law. In accordance with Section 2.1, the Administrator (a) may, in its sole discretion and on such terms and conditions as it may provide, further delegate in writing to one or more officers of the Company all or any portion of its authority or responsibility with respect to the Plan, and (b) has the authority to act for the Company (in a non-fiduciary capacity) as to any matter pertaining to the Plan; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">, that any Plan amendment or termination or any other action that reasonably could be expected to increase materially the cost of the Plan must be approved by the Board.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.9pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">13.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Eligibility to Participate</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. To the extent that the Administrator has delegated administrative authority or responsibility to one or more officers of the Company in accordance with Sections 2.1 and 12, each such officer will not be excluded from participating in the Plan if otherwise eligible, but he or she is not entitled to act upon or make determinations regarding any matters pertaining specifically to his or her own benefit or eligibility under the Plan. The Administrator will act upon and make determinations regarding any matters pertaining specifically to the benefit or eligibility of each such officer under the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6.15pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">14.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. This Plan will have a term commencing on the Effective Date and expiring on August 4, 2028 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) and shall, thereafter, automatically renew for successive one-year periods (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Renewal Term</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; and, collectively with the Initial Term, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) unless, upon the decision of the Administrator, the Company notifies the Participants who remain eligible for benefits under this Plan of the Plan&#x2019;s nonrenewal at least twelve (12) months prior to the commencement of such Renewal Term, in which case such Renewal Term will be canceled and the Plan will expire on the anniversary of Initial Term or the relevant Renewal Term, as applicable. If a Change of Control occurs, the Term will extend automatically through the date that is twelve (12) months following the effective date of the Change of Control. If a Participant becomes entitled to benefits during the Term, the Plan will not terminate with respect to such Participant until all of the obligations of the Company and such Participant with respect to this Plan have been satisfied.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6.1pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">15.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Amendment or Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. The Company, by action of the Administrator, reserves the right to amend or terminate the Plan at any time, without advance notice to any Participant and without regard to the effect of the amendment or termination on any individual; provided, however, that during the Term, the Company may not, without a Participant&#x2019;s written consent, amend or terminate the Plan in any way, nor take any other action, that (i) prevents that Participant from becoming eligible for the Severance Benefits under the Plan, or (ii) reduces or alters to the detriment of the Participant the Severance Benefits payable, or potentially payable, to a Participant under the Plan (including, without limitation, imposing additional conditions). Any amendment or termination of the Plan will be in writing. Any action of the Company in amending or terminating the Plan will be taken in a non-fiduciary capacity.</font></div></div><p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10.6pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">16.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Claims and Appeals</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:12.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	16.1.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Claims Procedure</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. Any employee or other person who believes he or she is entitled to any payment under the Plan may submit a claim in writing to the Administrator within 90 days of the earlier of (i) the date the claimant learned the amount of his or her benefits under the Plan or (ii) the date the claimant learned that he or she will not be entitled to any benefits under the Plan. If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice also will describe any additional information needed to support the claim and an explanation of why such material or information is necessary, and the Plan&#x2019;s procedures for appealing the denial, including a statement of the claimant&#x2019;s right to bring a civil action under Section 502(a) of ERISA following an adverse benefit determination on review. The denial notice will be provided within 90 days after the claim is received. If special circumstances require an extension of time for processing the claim (up to 90 days from the end of the initial 90-day period), written notice of the extension will be given prior to the end of the initial 90-day period. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision on the claim.</font></p><p style="text-indent:12.667%;font-size:10pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">	16.2.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Appeal Procedure</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. If the claimant&#x2019;s claim is denied, the claimant (or his or her authorized representative) may apply in writing to the Administrator for a review of the decision denying the claim. Review must be requested within 60 days following the date the claimant received the written notice of their claim denial or else the claimant loses the right to review. The claimant shall be provided the opportunity to submit written comments, documents, records, and other information relating to the claim for benefits. The claimant (or representative) has the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit issues and comments in writing. The Administrator will provide written notice of its decision on review within 60 days after it receives a review request. If additional time (up to 60 days from the end of the initial period) is needed to review the request, the claimant (or representative) will be given written notice of the reason for the delay. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision. If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice also will include a statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents and other information relevant to the claim, and a statement regarding the claimant&#x2019;s right to bring an action under Section 502(a) of ERISA within two (2) years after completing the Plan&#x2019;s claims and appeal procedures. Any action shall be resolved exclusively through binding arbitration in accordance with the terms and procedures of the Participant&#x2019;s Mutual Arbitration Agreement.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.6pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">17.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Attorneys&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. The parties shall each bear their own expenses, legal fees and other fees incurred in connection with this Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.5pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">18.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Source of Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. All payments under the Plan will be paid from the general funds of the Company; no separate fund will be established under the Plan, and the Plan will have</font></div></div><p style="font-size:10pt;margin-top:30.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">no assets. No right of any person to receive any payment under the Plan will be any greater than the right of any other general unsecured creditor of the Company.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.35pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">19.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Inalienability</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. In no event may any current or former employee of the Company or any of its subsidiaries or affiliates sell, transfer, anticipate, assign or otherwise dispose of any right or interest under the Plan. At no time will any such right or interest be subject to the claims of creditors nor liable to attachment, execution or other legal process.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.2pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">20.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">No Enlargement of Employment Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.	Neither the establishment or <br>maintenance or amendment of the Plan, nor the making of any benefit payment hereunder, will be construed to confer upon any individual any right to continue to be an employee of the Company. The Company expressly reserves the right to discharge any of its employees at any time, with or without cause. However, as described in the Plan, a Participant may be entitled to benefits under the Plan depending upon the circumstances of his or her termination of employment.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.2pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">21.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.	Any successor to the Company of all or substantially all of the <br>Company&#x2019;s business and/or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or other transaction) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under the Plan, the term &#x201c;Company&#x201d; will include any successor to the Company&#x2019;s business and/or assets which become bound by the terms of the Plan by operation of law, or otherwise.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.3pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">22.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Applicable Law</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. The provisions of the Plan will be construed, administered and enforced in accordance with ERISA and, to the extent applicable, the internal substantive laws of the state of California (but not its conflict of laws provisions).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.6pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">23.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.	If any provision of the Plan is held invalid or unenforceable, its <br>invalidity or unenforceability will not affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:5.55pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">24.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the meaning hereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:4.95pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:2.4%;">25.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. The Company hereby agrees to indemnify and hold harmless the officers and employees of the Company, and the members of its Board, from all losses, claims, costs or other liabilities arising from their acts or omissions in connection with the administration, amendment or termination of the Plan, to the maximum extent permitted by applicable law. This indemnity will cover all such liabilities, including judgments, settlements and costs of defense. The Company will provide this indemnity from its own funds to the extent that insurance does not cover such liabilities. This indemnity is in addition to and not in lieu of any other indemnity provided to such person by the Company.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Verdana',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6%;margin-top:10.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Tahoma;font-kerning:none;min-width:3.2627659574468084%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">26.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Additional Information</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="margin-left:6%;text-indent:-31.776%;padding-left:22.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Plan Name</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">:	Standard BioTools Inc. 2023 Change of Control and Severance Plan</font></p><p style="margin-left:6%;text-indent:-31.776%;padding-left:22.667%;font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Plan Sponsor</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">:	Standard BioTools Inc. <br>c/o Chief Human Resources Officer<br>50 Milk Street, 10</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.365pt;font-family:'Verdana',sans-serif;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;"> Floor <br>Boston, MA 02109</font></p><p style="margin-left:6%;font-size:10pt;margin-top:1.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Identification Numbers</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">:	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">EIN</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">: 77-0513190</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">PLAN</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">: 502</font></p><p style="margin-left:6%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Plan Year</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">:	Company&#x2019;s fiscal year</font></p><p style="margin-left:6%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Plan Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">:	Human Capital Committee</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Attention: Administrator of the Standard BioTools Inc. 2023</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Change of Control and Severance Plan</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">50 Milk Street, 10</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.365pt;font-family:'Verdana',sans-serif;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;"> Floor</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Boston, MA 02109</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">650-266-6000</font></p><p style="margin-left:6%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Agent for Service of</font></p><p style="margin-left:6%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Legal Process</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">:	Standard BioTools Inc.</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Attention: Chief Human Resources Officer</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">2023 Change of Control and Severance Plan</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">50 Milk Street, 10</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.365pt;font-family:'Verdana',sans-serif;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;"> Floor</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Boston, MA 02109</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">650-266-6000</font></p><p style="margin-left:28.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Service of process also may be made upon the Administrator.</font></p><p style="margin-left:6%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Type of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">:	Severance Plan/Employee Welfare Benefit Plan</font></p><p style="margin-left:6%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Plan Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">:	The cost of the Plan is paid by the Employer.</font></p><div class="item-list-element-wrapper" style="margin-left:6%;margin-top:1.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Tahoma;font-kerning:none;min-width:3.2627659574468084%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">27.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Statement of ERISA Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">As a Participant under the Plan, you have certain rights and protections under ERISA:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:2.7589560035999874%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&middot;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">You may examine (without charge) all Plan documents, including any amendments and copies of all documents filed with the U.S. Department of Labor. These documents are available for your review in the Company&#x2019;s Human Resources Department.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:14.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:2.7589560035999874%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&middot;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">You may obtain copies of all Plan documents and other Plan information upon written request to the Administrator. A reasonable charge may be made for such copies.</font></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">In addition to creating rights for Participants, ERISA imposes duties upon the people who are responsible for the operation of the Plan. The people who operate the Plan (called &#x201c;fiduciaries&#x201d;) have a duty to do so prudently and in the interests of you and the other Participants. No one, including the Company or any other person, may fire you or otherwise discriminate against you</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.78in;position:relative;box-sizing:border-box;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:15.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">in any way to prevent you from obtaining a benefit under the Plan or exercising your rights under ERISA. If your claim for payments or benefits under the Plan is denied, in whole or in part, you must receive a written explanation of the reason for the denial. You have the right to have the denial of your claim reviewed. (The claim review procedure is explained in Section 16 above.)</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Under ERISA, there are steps you can take to enforce the above rights. For example, if you request materials and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Administrator to provide the materials and to pay you up to $110 a day until you receive the materials, unless the materials were not sent due to reasons beyond the control of the Administrator. If you have a claim which is denied or ignored, in whole or in part, you may file suit in a federal court. If it should happen that you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:5.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">In any case, the court will decide who will pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds that your claim is frivolous.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:36pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">If you have any questions regarding the Plan, please contact the Administrator. If you have any questions about this statement or about your rights under ERISA, you may contact the nearest area office of the Employee Benefits Security Administration (formerly the Pension and Welfare Benefits Administration), U.S. Department of Labor, listed in your telephone directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W. Washington, D.C. 20210. You also may obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1.26in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">CEO Participation Agreement</font></p><p style="font-size:10pt;margin-top:8.1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-42.857%;padding-left:30%;font-size:10pt;margin-top:5.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. 2023 Change of Control and Severance Plan (as amended and restated, May 21, 2026) Participation Agreement</font></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) is pleased to inform you that you have been selected to participate in the Company&#x2019;s 2023 Change of Control and Severance Plan, as amended and restated (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) as a Participant.</font></p><p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></p><p style="font-size:10pt;margin-top:5.65pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement.</font></p><p style="font-size:10pt;margin-top:8.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Definition of &#x201c;Good Reason&#x201d;</font></p><p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of one or more of the following events effected without your prior consent, provided you terminate your employment with the Company within six months following the initial existence of the &#x201c;Good Reason&#x201d; condition (discussed below): (i) the assignment to you of any duties or the reduction of your then-current duties, either of which results in a material diminution in your then-current position or responsibilities with the Company including, without limitation, any negative change in reporting hierarchy involving you or the person to whom you directly report; (ii) a material reduction by the Company in your then-current base salary; (iii) a material change in the geographic location at which you must perform services (for purposes of this Participation Agreement, your relocation to a facility or a location more than 50 miles from your then-present location shall be considered a material change in geographic location); or (iv) any material breach by the Company of any material provision of this Participation Agreement. You will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#x201c;Good Reason&#x201d; within 90 days of the initial existence of the grounds for &#x201c;Good Reason&#x201d; and a Company cure period of 30 days following the date of such notice.</font></p><p style="font-size:10pt;margin-top:27.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Non-COC Involuntary Termination</font></p><p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">If, outside of the Change of Control Period, you incur a Non-COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:5.95pt;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:1.2%;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. An aggregate amount equal to 200% of your annual base salary in effect as of the date of your Non-COC Involuntary Termination paid in equal installments over a period of 24 months following your termination date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:5.45pt;justify-content:flex-start;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:1.2%;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA for a period of 12 months following your termination of employment.</font></div></div><div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:1.15pt;justify-content:flex-start;margin-bottom:30.75pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Tahoma;justify-content:flex-start;min-width:1.2%;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 4.3 of the Plan.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:30.75pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.53in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.76in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:3.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">COC Involuntary Termination</font></p><p style="font-size:10pt;margin-top:5.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">If, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><p style="margin-left:2.667%;font-size:10pt;margin-top:1.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">1. Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Tahoma;font-kerning:none;min-width:2.9633333333333334%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">A lump-sum payment equal to 250% of the sum of (x) your annual base salary (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), plus (y) the greater of (A) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), or (B) the average of the annual bonuses actually paid to you with respect to the three (3) fiscal years preceding the year in which your COC Involuntary Termination occurs; provided, however, that if the annual bonus with respect to the most recently preceding fiscal year has not yet been paid, your annual target bonus will be used as the bonus for that year in calculating the average. For the avoidance of doubt, if you incurred a termination prior to a Change of Control that qualifies as a COC Involuntary Termination, then you will be entitled to a lump-sum payment of the amount calculated under the preceding sentence, less amounts already paid as cash Severance Benefits for a Non-COC Involuntary Termination.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:5.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Tahoma;font-kerning:none;min-width:2.9633333333333334%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">A lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), multiplied by (ii) a fraction, the numerator of which is the number of days worked by you during the year in which the COC Involuntary Termination occurs and the denominator of which is 365.</font></div></div><p style="text-indent:2.667%;font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">2. Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA (or, for any period after expiration of COBRA eligibility, reimbursement of health insurance monthly costs up the amount of the COBRA premium that would be payable if COBRA were available at such time) for a period of 30 months following your termination of employment.</font></p><p style="text-indent:2.667%;font-size:10pt;margin-top:6.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">3. Equity Award Vesting Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. 100% of your then-outstanding and unvested Equity Awards will become vested in full. If, however, an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless expressly otherwise provided in the applicable Equity Award agreement, the Equity Award will vest as to 100% of the &#x201c;Baseline Number of Restricted Stock Units&#x201d; or &#x201c;Baseline Number of Performance Units&#x201d; (as defined in the Company&#x2019;s grant agreements) or the equivalent measure of the number of units or shares that vest at 100% of target levels of achievement under the relevant Equity Award. Except otherwise provided in the applicable Equity Award agreement, shares owed upon such vesting (and exercise if applicable) of Equity Awards will issued to you as promptly as practicable and no more than 30 days after they become issuable (whether through the vesting acceleration alone or upon an exercise of options following such vesting acceleration). Notwithstanding the foregoing, to the extent that the payment or settlement of an Equity Award is subject to Section 409A, the Equity Award will be paid or settled in a manner that will meet the</font></p><p style="font-size:10pt;margin-top:33.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.76in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:36.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">requirements of Section 409A such that the payment or settlement will not be subject to the additional tax or interest applicable under Section 409A.</font></p><p style="font-size:10pt;margin-top:1.15pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">4. Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 5.4 of the Plan.</font></p><p style="font-size:10pt;margin-top:1.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Additional Benefits</font></p><p style="font-size:10pt;margin-top:5.6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">In addition to the foregoing benefits, in addition to the Plan benefits described above, if, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, the Company will reimburse your reasonable attorneys&#x2019; fees incurred in connection with the review of the Release and any related separation agreements and documents, up to $8,000.</font></p><p style="font-size:10pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">General Provisions</font></p><p style="font-size:10pt;margin-top:5.6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">For clarity, any severance payments provided for herein that are based on annual base salary (and any reduction to base salary constituting &#x201c;Good Reason&#x201d;) shall be calculated without giving effect to any temporary reduction in base salary imposed by the Company or agreed to by you in connection with any global pandemic or comparable global or U.S. emergency that threatens the Company&#x2019;s economic position.</font></p><p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period set forth in the Plan.</font></p><p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:36pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">[Remainder of This Page Intentionally Left Blank]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.52in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1.26in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7.9pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that: (1) you have received a copy of the 2023 Change of Control and Severance Plan and Summary Plan Description (as amended and restated); (2) you have carefully read this Participation Agreement and the 2023 Change of Control and Severance Plan and Summary Plan Description (as amended and restated); (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors; and (4) participation in the Plan and this Participation Agreement replaces in its entirety any severance and/or change of control provisions set forth in any offer letter, employment agreement and/or Equity Award agreement, including, but not limited to, the Prior Plan, the 2023 Change of Control and Severance Plan Participation Agreement with the Company dated July 27, 2023 and your Employment and Severance Agreement with the Company dated Jan 19, 2022.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7.9pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"></td>
     <td style="width:13%;box-sizing:content-box;"></td>
     <td style="width:45%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">STANDARD BIOTOOLS INC.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PARTICIPANT</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:22.45pt;font-family:Times New Roman;margin-bottom:36pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">Attachment: Standard BioTools Inc. 2023 Change of Control and Severance Plan and Summary Plan Description (as amended and restated).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Tahoma',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature Page to the Participation Agreement]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.53in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>lab-ex10_5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-28T15:37:47.6627+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.5</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO Participation Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. 2023 Change of Control and Severance Plan (as amended and restated, May 21, 2026)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participation Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard BioTools Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is pleased to inform you that you have been selected to participate in the Company&#x2019;s 2023 Change of Control and Severance Plan, as amended and restated (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as a Participant.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to actually become a participant in the Plan, you must complete and sign this Participation Agreement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of &#x201c;Good Reason&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of one or more of the following events effected without your prior consent, provided you terminate your employment with the Company within six months following the initial existence of the &#x201c;Good Reason&#x201d; condition (discussed below): (i) the assignment to you of any duties or the reduction of your then-current duties, either of which results in a material diminution in your then-current position or responsibilities with the Company including, without limitation, any negative change in reporting hierarchy involving you or the person to whom you directly report; (ii) a material reduction by the Company in your then-current base salary; (iii) a material change in the geographic location at which you must perform services (for purposes of this Participation Agreement, your relocation to a facility or a location more than 50 miles from your then-present location shall be considered a material change in geographic location); or (iv) any material breach by the Company of any material provision of this Participation Agreement. You will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#x201c;Good Reason&#x201d; within 90 days of the initial existence of the grounds for &#x201c;Good Reason&#x201d; and a Company cure period of 30 days following the date of such notice.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-COC Involuntary Termination</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, outside of the Change of Control Period, you incur a Non-COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An aggregate amount equal to 200% of your annual base salary in effect as of the date of your Non-COC Involuntary Termination paid in equal installments over a period of 24 months following your termination date.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA for a period of 12 months following your termination of employment.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 4.3 of the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COC Involuntary Termination</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, you will receive:</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="margin-left:13.333%;text-indent:-8.333%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump-sum payment equal to 250% of the sum of (x) your annual base salary (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), plus (y) the greater of (A) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), or (B) the average of the annual bonuses actually paid to you with respect to the three (3) fiscal years preceding the year in which your COC Involuntary Termination occurs; provided, however, that if the annual bonus with respect to the most recently preceding fiscal year has not yet been paid, your annual target bonus will be used as the bonus for that year in calculating the average. For the avoidance of doubt, if you incurred a termination prior to a Change of Control that qualifies as a COC Involuntary Termination, then you will be entitled to a lump-sum payment of the amount calculated under the preceding sentence, less amounts already paid as cash Severance Benefits for a Non-COC Involuntary Termination.</font></p><p style="margin-left:13.333%;text-indent:-8.333%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to the Change of Control or your COC Involuntary Termination, whichever is greater), multiplied by (ii) a fraction, the numerator of which is the number of days worked by you during the year in which the COC Involuntary Termination occurs and the denominator of which is 365.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Continued Medical Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Payment by the Company of continued health coverage under COBRA (or, for any period after expiration of COBRA eligibility, reimbursement of health insurance monthly costs up the amount of the COBRA premium that would be payable if COBRA were available at such time) for a period of 30 months following your termination of employment.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Award Vesting Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. 100% of your then-outstanding and unvested Equity Awards will become vested in full. If, however, an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless expressly otherwise provided in the applicable Equity Award agreement, the Equity Award will vest as to 100% of the &#x201c;Baseline Number of Restricted Stock Units&#x201d; or &#x201c;Baseline Number of Performance Units&#x201d; (as defined in the Company&#x2019;s grant agreements) or the equivalent measure of the number of units or shares that vest at 100% of target levels of achievement under the relevant Equity Award. Except otherwise provided in the applicable Equity Award agreement, shares owed upon such vesting (and exercise if applicable) of Equity Awards will issued to you as promptly as practicable and no more than 30 days after they become issuable (whether through the vesting acceleration alone or upon an exercise of options following such vesting acceleration). Notwithstanding the foregoing, to the extent that the payment or settlement of an Equity Award is subject to Section 409A, the Equity Award will be paid or settled in a manner that will meet the</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements of Section 409A such that the payment or settlement will not be subject to the additional tax or interest applicable under Section 409A.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outplacement Services</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Outplacement services as described in Section 5.4 of the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Benefits</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the foregoing benefits, in addition to the Plan benefits described above, if, during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company will reimburse your reasonable attorneys&#x2019; fees incurred in connection with the review of the Release and any related separation agreements and documents, up to $8,000.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Provisions</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, any severance payments provided for herein that are based on annual base salary (and any reduction to base salary constituting &#x201c;Good Reason&#x201d;) shall be calculated without giving effect to any temporary reduction in base salary imposed by the Company or agreed to by you in connection with any global pandemic or comparable global or U.S. emergency that threatens the Company&#x2019;s economic position.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable within the requisite period set forth in the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Remainder of This Page Intentionally Left Blank]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"><br> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that: (1) you have received a copy of the 2023 Change of Control and Severance Plan and Summary Plan Description (as amended and restated); (2) you have carefully read this Participation Agreement and the 2023 Change of Control and Severance Plan and Summary Plan Description (as amended and restated); (3) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors; and (4) participation in the Plan and this Participation Agreement replaces in its entirety any severance and/or change of control provisions set forth in any offer letter, employment agreement and/or Equity Award agreement, including, but not limited to, the Prior Plan, the 2023 Change of Control and Severance Plan Participation Agreement with the Company dated July 27, 2023 and your Employment and Severance Agreement with the Company dated Jan 19, 2022.</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"></td>
     <td style="width:13%;box-sizing:content-box;"></td>
     <td style="width:45%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">STANDARD BIOTOOLS INC.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PARTICIPANT</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Thomas Carey</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Egholm</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas Carey</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Egholm</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chair of the Board</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/22/2026</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment: Standard BioTools Inc. 2023 Change of Control and Severance Plan and Summary Plan Description (as amended and restated).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A - </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>lab-20260521.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-05-28T15:37:47.9288+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.standardbio.com/20260521" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:lab="http://www.standardbio.com/20260521" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.standardbio.com/20260521/taxonomy/role/Cover" id="Cover">
        <link:definition>75000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.standardbio.com/20260521/taxonomy/role/DebtScheduleofDebtDetails_1" id="DebtScheduleofDebtDetails_1">
        <link:definition>75010 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1" id="LeasesOperatingLeaseMaturityDetails_1">
        <link:definition>75020 - Disclosure - Leases - Operating Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.standardbio.com/20260521/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails_1" id="IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails_1">
        <link:definition>75030 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.standardbio.com/20260521/taxonomy/role/DebtScheduleofDebtDetails_1" xlink:href="lab-20260521.xsd#DebtScheduleofDebtDetails_1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1" xlink:href="lab-20260521.xsd#LeasesOperatingLeaseMaturityDetails_1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.standardbio.com/20260521/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails_1" xlink:href="lab-20260521.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails_1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.standardbio.com/20260521/taxonomy/role/Cover" xlink:href="lab-20260521.xsd#Cover" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Excluding Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: term loan, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less deferred tax assets included in other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying value of all Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum payments (receipts)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Deferred tax liability per balance sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.standardbio.com/20260521/taxonomy/role/Cover" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.standardbio.com/20260521/taxonomy/role/DebtScheduleofDebtDetails_1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtNoncurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtCurrent" order="1" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.standardbio.com/20260521/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails_1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="1" weight="-1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 21, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 21,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Standard BioTools Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001162194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0513190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">50 Milk Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">10th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">266-6000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LAB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lab-20260521.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.standardbio.com/20260521/taxonomy/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="lab-20260521.htm">lab-20260521.htm</File>
    <File>lab-20260521.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lab-20260521.htm": {
   "nsprefix": "lab",
   "nsuri": "http://www.standardbio.com/20260521",
   "dts": {
    "inline": {
     "local": [
      "lab-20260521.htm"
     ]
    },
    "schema": {
     "local": [
      "lab-20260521.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 37,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.standardbio.com/20260521/taxonomy/role/Cover",
     "longName": "75000 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lab-20260521.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lab-20260521.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Less deferred tax assets included in other long-term assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "negatedTerseLabel": "Deferred tax liability per balance sheet"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Net, Total",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum payments (receipts)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/LeasesOperatingLeaseMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/DebtScheduleofDebtDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Net carrying value of all Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/DebtScheduleofDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Debt, Current Maturities, Total",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Less: term loan, current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.standardbio.com/20260521/taxonomy/role/DebtScheduleofDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Term loan, non-current"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.standardbio.com/20260521/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-26-245181-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-245181-xbrl.zip
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M3[==GP8@9]3R>1=6)]>DGF^V-4,+=%O7UCJ-WX#56?C_(I&^E(T:/H:N=5<
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M['UM3*OH=A_V/MN))RJS7J5A;UUF_8>6&_NC3S]]:/7S0?CIOU!+ P04
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M]AQ<PP"!\]%@]-X8G!JCCX_#T_.3#^?O/AR?C3Y^_.M@<#X8I*J1Q=*S9_,
MO#'? E:+MNVZ"&.T!%]L%[JF#3%X$*T>@1O7/ 97&(/OK)H/OB,?>4_(.HZ(
MOOC6N1\Q$4!OAH([Z"!_ 4UTT4NQX@?0M:!G36S"&6$M#TY'PQZ 0>#9DS!
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M5@R\FGP5C+IFQUK=/DH--+;LGH-@-=QT#;4-CZGK]A=OYB@;_WJ4A#@NCT!
MP 2!>VA;1X U!UA[7>?_"7D3DO0RM6@^['.AE@[O:W950@,P(JU%FYX\^B"O
MBSK8A@M*VS!3Q$%$'43D :??)=YP.]@JCKG8SBB/*1Z!B":@1#49XKO@16%_
MZV:H=N"(SC6(-]AY">16H5-MHS0=1+.C"1?_ (PF^.;JFW';\%(VX70RE(X@
MJMD?R85!1J.M6-/RU@98&0*UW:B/B0%.#5!RK<>O&.D-,*&.[=J1!DI\4X)N
M5_@ITT+:F%H?O597,8E[=*O;=O%UNB- J7:'GZQG %B"LX"R!*,;@K2+<&C1
M9[8+2#"GMC1F7A'N0XB*:-PM[&L/U-#F9P_;'AV<J)Q3._&PM1FP-%F2&6"U
M'77*04LU!#"AYRW9IN0)XI#?\H<8@SL2[,^561H[NC?[]O&9=(*A*IL/G;RL
MHF5WQ DCR)9[1K(#7)0-,%VLJ *#:_:&( 4$+<"(M1U\NA/T<Z",>=Z&A9@@
MD"FVG@7<%'IE//>V7H2(&*#4>$J[UN-7>A8T,5$>G+Z-#2+E($G1Y#LG3>?#
MN^$JNQE4,=1R3@HS@7!34=H,8N$G;I63^IEH==+OSPS3Q'W.0?]N_Q;9ZBK%
M=B8,RTYT90: T0,1P3:#5]B1FI!+-T5JRIS3 /\15/[;6KQI,>L"O>WE%9TZ
M:X_'/+K%D.YJECBK+7Q)MW,T]2UD;;8O?&DK4<B+T^,<>8BSJ6.S*FXPU>P^
M7I<YTX:C-Y.W0%!M,W(I_%0_?.F*5EVI1S1 1*2U:"5):X&\Z;35HK2ZRFQZ
M]\JW2& :!BS;IF.[MA,Z8!'3!F\\9")[$23),_=HF,KWZ[9SU:YH[=VUM@OP
M"LM:(P?I.X1UC6ON5*8T]A[(MPU8R;+6ACA_$W(KWW%"#0AR[0:/M>.N>(%S
MAZ$233G)=L29Y)=MQ$6V*X8*\^D6\ 7HV@HF$+-/70!_CO;7=6NOYFZWX+%1
M*%/5YE#:$3^*-; 1IK+WDFM'@5 R@-/I &@Y$D07\KHWI[5>I:+M=9W_G(_\
M_?ZU@O(&^78Z3I $$4T0$^T(+PK]5I^A*T_.$P ]4V"),_>7P!&Y_4U"5[U%
M8$12CJM//>)4S^\L0)#-KKL7)1+8-UO5LD,S;BI<C&X3$^-J'(S;!+]FMFB)
MMSIW4)MB/'=Q,SM[\K<ZFX1:-;.T0%_I$F23#!5? 52KL<++@EV:.5+>Z;I3
M9W5SKC7]I\I&K>R^W,VS)EE0Y:@6J'-7MIJ7=4'F:EG.JCM/S4,OSV>M'"FJ
M"T)-3_7U>:W3<WK--9H6K2;5UY&VK"!E6:^+S*W&I5X8TE]598[:Q4(^0[:2
M@4RH?)/PR_)F"^R%X>5- B_-IBV0%\=DMV&55>;8SBZW^8#FIC5,>:YME;Y7
MQ,HVS43-G-NU+=0X<+1Y397/Q"VKJ$SX99. E?FY!=I\"&-7AE11GNXZ8TL9
MX-<502CS==>10CX&K@U+:C:+=W8YE<+(F@2LS.TMT.;CL+HRO+8948WWB2IJ
M1ZVP%9$]C2IM13[P1&=G8V,:G::%6<*3B:J.+6EZ_%?,%EZZ\5:$+S0_VM?D
M$)>'?=FI?I.L%&46%^B5)^%-#ZFZ&<9KGW6(0^+F!UUIWG%YR!4?LZ8_OYLZ
M'+VEOU)O^(OL=]OCEG(LU?EL</S1WFP3\FFRYF_W-O"1G4Y^B[&57V]MP=?
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MHAC'B%W<-:DP=6SN]/[![^L8E"8&6Z:2H"\$,9M22?A3KN%%?T ;[9]6!R4
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M^D1,^I<!..AJF;)QQ'K ;LE'3#HAK3Y+$0?9=G:_7QA!6@M%'+@X;PGYLF=
MQP0M46$L8Y6ES^F0G8++D6-4DP!#WP5E7J[0@6\.X*KDEO,6M=G\_HKL=5SA
M)FK+_G>4LY_M$6=_:]K^ K/!GK@B;@ZDM04&;8'!(P>:M@4&]^Z<\:I-;GT2
MIM=OYT1O(!,^96D(6ETF6:-Q S)=>-2,/;N=H*T<*WE#R7R>G['B8_2F+-:T
M-522>1@C]L;'C]<B>LUQ5WCF=0^+2)W9+$4&V\CL\$U7($@Q%UP75<48GDI,
MRFLYS];S6*Y(=B-5=]VRPO>V5MRX-7 L^9#K56U @1[J!$N1#\S8;E/>C'Y@
MK@@N=^$*&6T&IW"FA;&6Y!T(9>5F?EG7J(EE::?[XS=-JDY&&;_>7=3;M%H
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M2S?:5A?MV,6U9LT.('P9X6Z+C%H2V!>X;94$VMKKE@;V$&YM]&*/+Z]%^AU
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MXJ4&10S^+G2:D"PQ0]]][_8H-<-S>"^-LN+^%@K@\N#EF"C7U<%!(4 T1V7
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M![<32;5N^21+BS&K[':SPF,K8)*;\D(ZE$C*4V#EX8RC'J5R4#FUO]#A6L7
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M.W[&^KA??AZFT?Q/__[+SY-\&O_I_P-02P,$%     @ IJ"\7&/$]%5<$@
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MG -$*HR!VPTBF&;R&) '9^,L 51H/$4H 2]YH2R75RM"EK@YK) !=N5(QI(
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ME51\Y8?E29H<22T)O,F1-#F2)O[;Y$@>#(R+_W8P_IMY7V:>(CET*1(4T3@
M?MRY::W-F#PP)+RL7^ [6O-.G4(A5^1-#+M.\%VUT*TVRV(,1L]:OA"%/B9
MAX\/7C\EI%1G=.S+Y+PC6!3N>%0B:&C6%?7#E$"J5H]C^5I5HT9:@*<'GA/,
MQ@@WN&FH.DLG<#'J?1_@/N0]*.L.VRQ24SQ'VSW9D,O@KH0K4<:2#D\M8;0
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M>S]UZ5]_-3XGCG^&*@ZK"-Y[,@1_N(GD4%KF),O:Z.TV4@)87>BGP I-&HI
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MVNT>VY+;- $W*+L(*J_U8&8$*<RM!'S#[G 8:,4\*%B6M@-/T[9#HO6#6TS
M/D"DPA@XW2""UTP> _)@;YPE@ J-NP@EX"4OE.7B;$7($A>'&3+ KAS*6!)
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M\Z.J5P);:HL&MR3H.Q/LA^,IYD#>X&(%9:E5H*AA!F#)E];C"HHJ/$5MHV+
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M?V%A1%A6?M';4+CO8_NFUBG[9C9%!Q?[$XY&Z$\8==7>5'@@TMU<.J,# VE
MI>NX_V*"6!B,W43>JTI_$'H8TUD@NY8D5BJFVG?4N+:H/?I.29":"H&[TGF2
M?^AXZWDR%6-H:ZMF-RL!'!CUQW&G\?6.DH)?'QY5G-R3*K"[14!445",57Z'
M2T0A,=9('[R7UFK[$ZMHXZS;"1#::!N!T/1TMCM"S A?YJQ8R@L!4C:*F Y,
MQ& -+><B5 (0H>)6E/XFLYENE8(E5B5Y"L>I0-ILD[$:L$@&>LII$<(*?F_B
M7*('"E^&'5TL9+W-J(O)$W.7TV">!P3Y(I4B-;C&+I%%:WKU]L(?:A0(&>XR
MB0RH!R%M4R(#OTKCH Q'--'A2;$'!3 L<*(2]:J0@_HU%C(>@'5\,#%LF#S,
M%_&OL>$4(K54P^+3.U5^A5Q"6JT0IKTR513.FT%Y*+E"X2 FH)W/HZ N'%9$
MN/<0@\<V6#<\"<+86$OEUE*6;9$<:BI:S)X&RVF.P&9%2VPF>X<Q[ U1KT0^
M5.15A>23.D:HWAW<>$!SND/KGSS<BPK>OP-E(_@;/-B\&&<%PM"-G*_R1:VW
MN>-0!3!2(RRTK?EK_W._!&W:D[BF7+\;'=$CS!UVC>^4;96%"'TM;-GDT4_I
MC&J%)U=C!K2QOS;VU\;^[C&?UVWL[T<(2K6QO[U&+3KIC]NDV&=/BAWM>U+L
MQ/)"-["=KD3FM*USY3=GJ'\J5#86M:P+M%9%G9MK>GK3X,5G@[00R(W _ 5]
M-P!5$MLZ:V^FLEEQ8F4/$>7:2VNWTJ&@AW/(O"<D;?T[2B+%0 !U!N T>\^%
M_0ZR==^9$#JN1WX4]K<IG&GZ#1J-[E<15>\#6=)@0:[L<G/R&RA5N@BL6CV*
M-(/)R\MX\[ZVC\V(TKY5=2,*$=7$IFH@;&,V%AA-5WEOG#D\)N.1[FVPQ&:\
M<9I2G00YF@45=&#4B&D@=#G"70YQ:,#[_K!712AN%\WPK1Z,6)X)%];C)YX!
M_V+O"%KRTL?40]!8.AX?9/Q<5G(HC&(X W)9)<X2 U;Q;!9XB 1>;!ZN&B=P
M'S_=-X%@RO-L$2=8D<&Y MAK5-5H;#]MQ/I?2'1:,PHUHLAT;TS=Z9R"6&B6
M&=)5--F5[3;PN:6+!3AX>)FL +3>>[$#I7;WR<8;G1H;)P)5L!LC_61+HT-.
M!> *Q5B)90XK:8 _M4"'/9/5BW3!1G40>0F# B'6CX&^HJZRMJ23H$$2I=Z(
MVS<QR+#G+> \:Y6=9U=VQONN[+RW2MB [DWB3/.*ST$W*36ID!DWQ1MK0:E>
M?+/XI92"K;?#/:^>BC0! Z?>'W(<820!^K@DD$<RT;6IK#"E)FGH.+3*#UG'
MT?(EF%540G).QX+FFL+_!#*VARC[$GX![RS"OL?E((1Z 4 =/8AS$% RC")O
MJ=2^IF0NE,>B+[:;0,<WNAZ'P/TM$BI&"ZJT2=E$7LZ.T>UW,+W,%/F6YX05
MN1MG49KH,PIJV>*BE=3/*ZF/]UU2(UQ@$V5RL5":DF1=-H4DSHNT89#7WFOT
M&HU* UI7D,A')OD<U:GCGC,:C%[O(2CB)<9;W=!IY%F9$CT-/D 6'W#FC$ "
MT!6-:&<L5,&"%#=D]X#@Q*@V'AN,?T3IS9RZG3H=$JWN?AW3%2ZMZ<>$I]0#
M'@I#9AD;Y\ZFLSTL9VWTOG=!-\"633W3.TB[EZ0J6-!HBADCH(<%.CG0SM_
MYD42!\@@6LQJ:C8XU<*8F2:U%9:02.H%[1?1L$ 'OA'A-297CW3"=2&[0^%M
MJ=P.4H1L'B#O#G=F(GBOC0=*3>JDE[&8)42"7&>!EW*+;8)UI"L%<:>O,8FC
M.!7,EM-Q<=G:LJ+3%/:0E "^9H9D&?@E068C/E'J,!D.Z-7<W+=BGK4!6[-3
MCC<F(R=IYZ5HN#9+)=<';<%=&08V&XFJO(%W+/NLZ&R*7?:P6)@<8CR_> KD
M)?7HLMM,8546$6O+7C%%@7293Q&W4B6]/JM+ S3E5E%^=D7Y9-\5Y8GM#;1
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MNRZ/0F[^!HF4>,E@C&CZX^Z<>(A F40QZ.T($B]?8JJR9ZKQ^#" W'2H")&
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M6P(OXE!8G6#9Z4 =HW6_#ZU?4M/7(L3&1HM<;-?:=_ZA/!<%0&O]B>H275@
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MD8?.O*;P@C#>Y&0>%K_=,D*/Z,\604 GLX 0D23M)J;A^2P)KN%H\G0G=//
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M I7-U\&5HY07R%V[K?<_:^C#N&8L,?&/U/198[>YN%S;.]M8O%^]C/CN_RD
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MOD+S/O)IK?I4:WVJ]?.ON'S$4ZV'.R,5SM_^<+@3V21^^W]02P$"% ,4
M" "FH+Q</TZL0U(=  "*4@$ $               @ $     ;&%B+3(P,C8P
M-3(Q+FAT;5!+ 0(4 Q0    ( *:@O%PL.4(_3P\  *3+   0
M  "  8 =  !L86(M,C R-C U,C$N>'-D4$L! A0#%     @ IJ"\7"/9I$ZC
M2@  =X@"  X              ( !_2P  &QA8BUE>#$P7S$N:'1M4$L! A0#
M%     @ IJ"\7&/$]%5<$@  6[4   X              ( !S'<  &QA8BUE
M>#$P7S(N:'1M4$L! A0#%     @ IJ"\7)8RXQ-P$@  #[@   X
M     ( !5(H  &QA8BUE>#$P7S,N:'1M4$L! A0#%     @ IJ"\7'(]S^'I
M2@  [',"  X              ( !\)P  &QA8BUE>#$P7S0N:'1M4$L! A0#
M%     @ IJ"\7+/!9U;H$0  $IX   X              ( !!>@  &QA8BUE
?>#$P7S4N:'1M4$L%!@     '  < J $  !GZ      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>lab-20260521_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lab-20260521.xsd" xlink:type="simple"/>
    <context id="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001162194</identifier>
        </entity>
        <period>
            <startDate>2026-05-21</startDate>
            <endDate>2026-05-21</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_598da5f5-87b0-4237-9990-99cb2f9aa57a">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_3e6564b9-1b2f-414d-82d2-9a66f1ede7f1">0001162194</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_c9c093fe-deb7-4060-87b4-180b145c9447">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_9f7dc7a2-1770-477d-a218-c8f8b16d8d61">2026-05-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_a0ea5844-17c2-4f24-8f11-98c9f5191673">Standard BioTools Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_f0781409-1d90-4467-bc90-c9fd3b8e5b8a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_cf3c254c-baef-488b-b243-fcb3003ed9f9">001-34180</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_3cc45e3e-e08d-4b9a-8a6d-52c470d34086">77-0513190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_52601732-0d5e-49da-b700-e119fab26516">50 Milk Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_7ae3452d-d8b7-46a1-a638-27ecea327d11">10th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_16a67af3-7376-4bfb-bb5e-f18a6f9695a8">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_342434ff-a242-4767-a83b-c946ef35f7fa">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_3bec15bd-f7af-4de9-b7b3-cd36020f1510">02109</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_a31c211e-dc13-48c6-84e0-e5675743740f">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_548f9525-304e-47c3-962d-a28f41987f18">266-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_2c1392a0-0ca5-4eaa-884b-298a442eb3f1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_b44c5859-0c5a-454a-9f83-af96c0eb08e5">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_d8f814e4-b7d3-4dc1-a961-59ecb5a3ed87">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_2b2b678d-08c5-40ed-b75e-5dfb2ae372f5">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_a7b3f892-ad6b-466f-8145-2327f1e41e4a">Common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_4c809a99-ba97-4c14-af53-ba6e40ae0205">LAB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_c26e2d3e-fabd-4806-bd04-fef080d84c2b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_3d2fc1c4-7170-4a57-bf3b-64f4fb0bf041"
      id="F_4b50b7a5-d362-4374-8d37-57aecff265ba">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
